sentence	label
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
To evaluate the of HAART on the clinical of , systemic , HIV-NHL compared group of patients with who with the cyclophosphamide @DRUG$ , vincristine @DRUG$ ( CHOP ) chemotherapy plus HAART group or a regimen cyclophosphamide teniposide prednisone with bleomycin ) without receiving antiretroviral therapy .	DDI-false
, lidocaine/quinidine phenobarbital/valproic acid @DRUG$/lidocaine and .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-advise
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
acetaminophen/theophylline lidocaine/quinidine , , phenobarbital/valproic , , and @DRUG$/phenobarbital .	DDI-false
For it felt that , in most subjects an drug benefits @DRUG$ a @DRUG$ not outweigh risks and failure	DDI-effect
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
the of plus the with systemic non-Hodgkin ( authors 24 with who were with , doxorubicin vincristine and @DRUG$ ( regimen plus with of patients who were treated with CHOP a CHOP-like i.e. , , @DRUG$ , prednisone plus bleomycin receiving therapy	DDI-false
Other Drugs such @DRUG$ , , , @DRUG$ , antidepressants associated of .	DDI-false
Acetaminophen, lidocaine, @DRUG$, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Agents Causing Renin Release : The antihypertensive and @DRUG$ antihypertensive that renin ( , @DRUG$ .	DDI-effect
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	DDI-effect
The effects of concomitant @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
diuretics ( @DRUG$ , , , @DRUG$ supplements , or salt substitutes lead to increases in serum potassium	DDI-false
@DRUG$ prior of diphenidol may decrease emetic response to @DRUG$ in of .	DDI-false
: toxicity receiving @DRUG$ concomitantly cause sodium @DRUG$.	DDI-effect
evaluate the plus on the clinical with systemic ) , the a group with who were with the , vincristine and prednisone ( CHOP ) plus a 80 patients who treated regimen ( , cyclophosphamide , doxorubicin , @DRUG$ , prednisone vincristine without @DRUG$ therapy .	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	DDI-advise
, no effects on @DRUG$ times were a involving administration of warfarin and	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
Agents Causing antihypertensive effect of @DRUG$ and IV augmented by @DRUG$ that cause renin release ( e.g.	DDI-effect
Concomitant cyclophosphamide, @DRUG$, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
To the of chemotherapy plus the patients with , lymphoma HIV-NHL , the compared 24 HIV-NHL who were the , doxorubicin , vincristine , and CHOP ) chemotherapy plus HAART group 80 treated with or , @DRUG$ , @DRUG$ prednisone with vincristine plus without receiving therapy .	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-false
Coingestion of @DRUG$ , and @DRUG$ with high to concentrations decreases binding of	DDI-false
and @DRUG$ should be administered extreme caution patients being treated with monoamine oxidase inhibitors tricyclic antidepressants because of @DRUG$ on may potentiated agents .	DDI-false
The @DRUG$ @DRUG$ not pharmacokinetics either alcohol acamprosate	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
, phenobarbital/acetaminophen phenobarbital/valproic , theophylline/acetaminophen .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
@DRUG$ - diphenidol may decrease the @DRUG$ apomorphine in the of poisoning	DDI-false
The of on the @DRUG$ requirement of our patient appeared be maximal to days after initiation @DRUG$ and extended a time after .	DDI-false
is currently available HMGCoA reductase @DRUG$ , @DRUG$ ) , unique agents	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ has been shown to beta-lactam antibiotics , including @DRUG$ based in vitro time kill with enteric	DDI-effect
The effects of @DRUG$ ( RR on the patch-clamp whole-cell recording in with fura-2 .	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
In this , this report @DRUG$ @DRUG$ under acidic conditions similar to those in vivo , resulting .	DDI-false
of volunteers doses @DRUG$ by a dose of Gleevec , @DRUG$ oral-dose which ( p 0.05 mean cmax 8) .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ and @DRUG$ have affinities for opioid and possibly nicotinic receptors , has much lower than NMDA and sodium , and the transporter .	DDI-false
that alter @DRUG$ concentrations may imatinib concentrations Caution when administering @DRUG$ with inhibitors of the family ( e.g. , ketoconazole itraconazole , ) .	DDI-false
structurally from the other currently available @DRUG$ ( lovastatin , @DRUG$ ) , unique properties the other agents of class .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
, lidocaine/quinidine , quinidine/lidocaine and .	DDI-false
@DRUG$ have for opioid and possibly affinities than @DRUG$ NMDA and sigma-2 , the .	DDI-false
The effects of ruthenium red (@DRUG$) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
@DRUG$ , Diuretics : Concomitant xanthine derivatives @DRUG$ or diuretics may potentiate hypokalemic beta2-agonists .	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
These dexamethasone retinyl acetate , and possibly and , regulate the proliferation epithelium by a dose-dependent modification of the activity @DRUG$ and @DRUG$.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	DDI-false
lidocaine/quinidine phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine and valproic acid/phenobarbital	DDI-false
, and : Concomitant derivatives @DRUG$ or @DRUG$ may a possible effect of   beta2-agonists .	DDI-false
caution when @DRUG$ a narrow therapeutic , cyclosporine @DRUG$ .	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
dexamethasone retinyl affected the proliferation of epithelium RPMI1640 alone , they modify the effect of @DRUG$ and	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Concurrent possessing nephrotoxic , ) myelotoxic e.g. cytotoxic e.g. ) e.g. , @DRUG$ @DRUG$ increase toxicity in these organ systems .	DDI-effect
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
, following concomitant of @DRUG$ e.g. , , , antiemetics , @DRUG$ tranquilizers )	DDI-false
@DRUG$ @DRUG$ or receiving oxidase or phenothiazines severe prolonged hypotension .	DDI-false
of @DRUG$ anhydrous and aqueous @DRUG$ solutions .	DDI-mechanism
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Anticoagulants indandione , and @DRUG$ such @DRUG$ ( NSAIDs and may the risk of bleeding when administered concomitantly with ardeparin	DDI-false
Acute symptoms treated a inhaled @DRUG$ such @DRUG$ ( the physician provide and instruct the patient how should be used	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Cardiovascular : Enalapril enalapril IV have used with beta adrenergic-blocking agents , @DRUG$ , nitrates agents , , @DRUG$ and of adverse .	DDI-false
To impact plus on the clinical with , systemic lymphoma HIV-NHL ) compared retrospectively of 24 with were the @DRUG$ , doxorubicin , and ( CHOP ) chemotherapy with a of 80 patients who were treated with CHOP chemotherapy a CHOP-like ( cyclophosphamide , , teniposide and prednisone with vincristine plus @DRUG$ ) receiving antiretroviral .	DDI-false
no impact the Cmax AUC , although significantly decreased @DRUG$ tmax 44 % the exposure to @DRUG$ % .	DDI-false
The results raise the possibility that ethanolysis reaction occur in stomach who @DRUG$ and @DRUG$ a basis	DDI-mechanism
possibility of effects @DRUG$ or @DRUG$ can by discontinuing the diuretic or increasing the prior to initiation of treatment enalapril or enalaprilat	DDI-false
In with @DRUG$ or @DRUG$ , the of atomoxetine is approximately and Css , max is about to greater than alone	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
alter imatinib concentrations Drugs that imatinib plasma concentrations : when administering @DRUG$ the CYP3A4 ( @DRUG$ , itraconazole , , clarithromycin )	DDI-advise
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$, @DRUG$, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
acetaminophen/theophylline , , phenobarbital/valproic acid quinidine/lidocaine and acid/phenobarbital .	DDI-false
immediate not coat-core of @DRUG$ @DRUG$ about % .	DDI-mechanism
@DRUG$ : Concurrent of aspirin @DRUG$ plasma possibly by competing sites	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
Molecular basis the @DRUG$ for and @DRUG$ animal .	DDI-false
Dosage adjustment of @DRUG$ be necessary CYP2D6 inhibitors , e.g. , @DRUG$ ,	DDI-advise
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	DDI-false
Coingestion of @DRUG$ , phenobarbital with , and valproic with @DRUG$ to concentrations binding the target	DDI-false
, additional interaction niacin @DRUG$ not demonstrated on and administration a @DRUG$ resulted no difference in of of relative to data	DDI-false
of @DRUG$ @DRUG$ , sedatives	DDI-false
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
To impact chemotherapy plus HAART clinical systemic non-Hodgkin retrospectively group 24 HIV-NHL who were treated with the doxorubicin vincristine and @DRUG$ ( ) regimen HAART with 80 patients were CHOP or CHOP-like regimen ( cyclophosphamide doxorubicin with vincristine plus bleomycin without receiving @DRUG$ therapy .	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ tranylcypromine sulfate and pargyline HC1 : of L-tyrosine and non-selective @DRUG$ may	DDI-false
Anticoagulant was during the of @DRUG$ , @DRUG$ and ;	DDI-false
acetaminophen/theophylline lidocaine/@DRUG$ , phenobarbital/acetaminophen , acid , , acid/phenobarbital .	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
the @DRUG$ , , @DRUG$ can used they toxic ;	DDI-false
that may alter imatinib Drugs that may @DRUG$ concentrations Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( , , erythromycin , @DRUG$	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
apomorphine - prior ingestion @DRUG$ decrease the response @DRUG$ in the of poisoning .	DDI-effect
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ and Tricyclic Antidepressants : FORADIL should be patients being inhibitors or antidepressants because of @DRUG$ on the system be potentiated by these .	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	DDI-advise
structurally distinct from the available @DRUG$ lovastatin , @DRUG$ ) , unique biopharmaceutical properties relative of	DDI-false
However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concurrent of @DRUG$ the treatment of blocks ) and @DRUG$ severe , persistent accidents	DDI-effect
@DRUG$ acidic such as @DRUG$ or from their binding sites	DDI-mechanism
@DRUG$ ('Seroquel') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Hypersensitivity have been reported receiving combination regimens containing high dose PROLEUKIN @DRUG$ specifically @DRUG$ tamoxifen interferon-alfa	DDI-false
Other Drugs quinidine @DRUG$ procainamide , antihistamines and @DRUG$ may associated QT-interval prolongation an increased risk	DDI-false
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
Gleevec increase of other CYP3A4 metabolized , @DRUG$ , HMG-CoA reductase )	DDI-false
that ( e.g. , @DRUG$ , @DRUG$ rifampin or	DDI-false
acetaminophen/theophylline phenobarbital/@DRUG$ , phenobarbital/valproic , theophylline/acetaminophen and valproic acid/phenobarbital	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving @DRUG$ therapy.	DDI-false
Co-administration of naltrexone with @DRUG$ 25 in AUC a 33 % increase in of @DRUG$.	DDI-false
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.	DDI-effect
Both @DRUG$ and block and dopamine release nucleus accumbens ;	DDI-effect
is therefore necessary be acquainted paraclinical @DRUG$ deficit to @DRUG$ due an insufficient magnesium intake only requires oral supplementation and magnesium depletion related to a of the mechanisms of magnesium status less specific regulation causal dysregulation .	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	DDI-effect
Concurrent administration drugs possessing e.g. aminoglycosides , @DRUG$ e.g. , cytotoxic chemotherapy , ( e.g. @DRUG$ ) hepatotoxic ( e.g. , effects with increase these organ	DDI-false
In addition to pharmacological this novel reaction between @DRUG$ ( a @DRUG$ under similar those found resulting in a product .	DDI-mechanism
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
additional niacin demonstrated effect @DRUG$ administration to patient population @DRUG$ resulted difference in extent bioavailability digoxin relative to control	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ had no the of it decreased @DRUG$ and intracellular exposure %	DDI-mechanism
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
The and time of @DRUG$ glutethimide and @DRUG$ were systematically 16	DDI-false
@DRUG$ : In some with compromised renal who are treated nonsteroidal drugs , the @DRUG$ may result in a deterioration .	DDI-false
@DRUG$ and 18-MC dopamine in accumbens @DRUG$ increases levels of serotonin in the	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
, acid , quinidine/@DRUG$ , valproic .	DDI-false
There significant increase in to @DRUG$ when Gleevec is coadministered with @DRUG$ CYP3A4 inhibitor	DDI-false
Hypersensitivity reported in combination regimens high dose PROLEUKIN agents , , dacarbazine , @DRUG$ , @DRUG$ interferon-alfa .	DDI-false
slightly the effect drugs e.g. @DRUG$ , methyldopa , @DRUG$.	DDI-false
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.	DDI-mechanism
The intensity uniformity and time course of @DRUG$ secobarbital , @DRUG$ chloral investigated in patients coumarin .	DDI-false
Higher concentrations of @DRUG$ ) - 10(-6 ) @DRUG$ ( ) - ) )	DDI-false
lidocaine/quinidine phenobarbital/acetaminophen quinidine/lidocaine , theophylline/acetaminophen valproic acid/phenobarbital .	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus clinical , ) the authors a of HIV-NHL who were treated with the doxorubicin @DRUG$ prednisone ( ) regimen a 80 patients who were with CHOP chemotherapy a CHOP-like ( , doxorubicin , , vincristine plus @DRUG$ ) without receiving therapy .	DDI-false
Concurrent drugs possessing e.g. @DRUG$ , ) , ( e.g. , ( e.g. , ) or hepatotoxic methotrexate @DRUG$ effects PROLEUKIN in organ systems	DDI-false
@DRUG$, but not @DRUG$, decreases heart rate at high doses.	DDI-false
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Drugs alter Drugs increase Caution when administering with inhibitors @DRUG$ itraconazole , @DRUG$ clarithromycin	DDI-false
intensity , of @DRUG$ interference by @DRUG$ , secobarbital , glutethimide chloral hydrate methaqualone were systematically 16 patients receiving .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
evaluate the HAART the of HIV-related , systemic lymphoma ( the authors compared retrospectively a group of patients who were with the cyclophosphamide @DRUG$ and chemotherapy plus HAART group who were treated with a regimen , @DRUG$ doxorubicin , teniposide and prednisone vincristine without therapy .	DDI-false
Similarly dialyzed @DRUG$ , quinidine @DRUG$ , alone at concentrations with ethanol different in serum	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
@DRUG$ and @DRUG$ the locomotor stereotypic effects	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	DDI-advise
Although @DRUG$ have shown to reduce effects including fever , insufficiency confusion and dyspnea concomitant these agents with reduce the effectiveness of PROLEUKIN and be avoided 12 @DRUG$ and other antihypertensives may .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Both toxicity of @DRUG$ the value amphotericin B can be cellular and by the following observations : i ) @DRUG$ differential	DDI-false
secondary @DRUG$ deficiencies indication physiological oral @DRUG$	DDI-false
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-false
, , phenobarbital/valproic acid , quinidine/lidocaine theophylline/acetaminophen , and	DDI-false
@DRUG$: @DRUG$ enhances the effect of warfarin.	DDI-effect
@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-mechanism
EM individuals with @DRUG$ or fluoxetine , the @DRUG$ approximately 6- to max is 3- to 4-fold greater alone	DDI-mechanism
It is chloral hydrate @DRUG$ be safely without in prothrombin test monitoring during oral @DRUG$ therapy	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Corticosteroids , @DRUG$ : with derivatives @DRUG$ , potentiate a possible of   beta2-agonists .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment @DRUG$ @DRUG$ potentiate a hypokalemic  	DDI-false
@DRUG$ have been side , insufficiency , , confusion , , these PROLEUKIN the of should be 12 and other antihypertensives the with	DDI-effect
These results suggest that dexamethasone and @DRUG$ , and possibly @DRUG$ , may modification the activity insulin and EGF	DDI-false
Higher ( - M ) @DRUG$ 3 10(-8 ) enhance the of	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
acetaminophen/theophylline , phenobarbital/acetaminophen acid quinidine/lidocaine , theophylline/acetaminophen , valproic	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	DDI-false
effect @DRUG$ on warfarin requirement of our patient appeared 5 to days the extended similar time after @DRUG$	DDI-false
Acetaminophen, @DRUG$, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	DDI-false
Co-medications that induce CYP3A4 @DRUG$ , @DRUG$	DDI-false
administration e.g. indomethacin , myelotoxic ( , chemotherapy ) , @DRUG$ ) or , , asparaginase ) @DRUG$ increase toxicity these systems .	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/@DRUG$.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
that may imatinib plasma concentrations Drugs that may imatinib : Caution recommended when with the CYP3A4 e.g. @DRUG$ @DRUG$ clarithromycin .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
that alter imatinib concentrations Drugs that : recommended administering inhibitors of CYP3A4 ( e.g. , ketoconazole @DRUG$ , @DRUG$ clarithromycin ) .	DDI-false
The @DRUG$ family of @DRUG$ drugs	DDI-false
The @DRUG$ @DRUG$ to patients receiving inhibitors , tricyclic antidepressants may severe , hypertension	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-advise
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	DDI-false
The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
a clinical study , @DRUG$ or @DRUG$ administered to hypertensive VASOTEC	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
may displace drugs @DRUG$ @DRUG$ from binding sites	DDI-false
of of azithromycin the disposition of @DRUG$ and @DRUG$ in HIV-infected	DDI-false
Concurrent administration ( e.g. , @DRUG$ , @DRUG$ , cytotoxic , ) or ( e.g. , methotrexate asparaginase ) PROLEUKIN increase these organ .	DDI-false
Other Cardiovascular Agents IV used concomitantly adrenergic-blocking agents , @DRUG$ @DRUG$ , digoxin evidence adverse interactions	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-effect
acetaminophen theophylline phenobarbital with @DRUG$ , and @DRUG$ at high to concentrations binding of drug .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ used with @DRUG$ .	DDI-false
Coingestion acetaminophen with @DRUG$ @DRUG$ acetaminophen , and acid with phenobarbital at high toxic concentrations the of drug	DDI-false
@DRUG$ tranylcypromine sulfate , sulfate , @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective inhibitors hypertension	DDI-false
effects of @DRUG$ were @DRUG$-induced .	DDI-effect
To impact of plus HAART on the clinical course of patients with HIV-related , non-Hodgkin lymphoma ( HIV-NHL , the authors compared retrospectively a group of patients treated the and ( CHOP regimen HAART with group were treated with or CHOP-like i.e. @DRUG$ @DRUG$ prednisone with receiving antiretroviral therapy .	DDI-false
lidocaine/@DRUG$ , , quinidine/lidocaine acid/phenobarbital	DDI-false
@DRUG$ binding of @DRUG$ a change of increase , 1732	DDI-mechanism
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
concomitant therapies : subjects treated with Acamprosate @DRUG$ hypnotics and sedatives ( @DRUG$ , or analgesics was that taking these concomitant .	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine phenobarbital/@DRUG$ , , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
initiation of @DRUG$ or @DRUG$ be precipitated by the , such sensation	DDI-false
These results suggest @DRUG$ acetate , and possibly other glucocorticoids retinoids may the proliferation prostate epithelium by a modification of the activity of insulin @DRUG$.	DDI-effect
@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Aspirin : of @DRUG$ may @DRUG$ plasma by for sites .	DDI-mechanism
epithelium proliferates in a defined medium consisting basal RPMI1640 containing , @DRUG$ ( ) , and @DRUG$ ( 3.7 micrograms/ml or )	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/acetaminophen acid , , , acid/phenobarbital	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
MAO inhibitors tranylcypromine @DRUG$ , and pargyline HC1 : use of @DRUG$ inhibitors may .	DDI-false
Therefore interactions concomitant of psychotropic drugs ( e.g. , @DRUG$ , @DRUG$ sedatives , tranquilizers ) .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
that may alter plasma concentrations Drugs may plasma : is recommended with inhibitors the CYP3A4 family e.g. @DRUG$ , , erythromycin @DRUG$ .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ major metabolite 6-beta-naltrexol were unaffected with	DDI-false
It is structurally the currently available reductase inhibitors ( @DRUG$ simvastatin , @DRUG$ leading biopharmaceutical properties relative to the other agents of class .	DDI-false
@DRUG$ to three cancer patients 0.025 mg to mg led @DRUG$ The effect of alternate-day of mg of drug metabolism in patients is	DDI-mechanism
, suggest @DRUG$ the effect of @DRUG$.	DDI-effect
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$ mg twice not @DRUG$ by 15 - 20	DDI-false
Concomitant @DRUG$, doxorubicin, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$.	DDI-mechanism
@DRUG$ effect @DRUG$	DDI-false
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
To impact of chemotherapy HAART on the with , the authors retrospectively a of patients with HIV-NHL were the cyclophosphamide , doxorubicin , vincristine , prednisone ( ) plus HAART with group of patients who were chemotherapy i.e. cyclophosphamide , @DRUG$ , and prednisone with @DRUG$ bleomycin antiretroviral	DDI-false
It is important understand @DRUG$ @DRUG$ AerolizerTM should in asthma taking .	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
implications of @DRUG$ interactions with @DRUG$.	DDI-int
and @DRUG$ block nicotine-induced release in the nucleus ;	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
neither @DRUG$ @DRUG$ the proliferation of epithelium in containing transferrin modify the effect EGF insulin .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
, when @DRUG$ a patient receiving @DRUG$ dosage reduced to prevent of prothrombin .	DDI-advise
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
Other concomitant trials safety profile in subjects treated Acamprosate concomitantly with @DRUG$ , hypnotics @DRUG$ or analgesics was to that .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	DDI-false
Based the results of studies @DRUG$ be safely both @DRUG$ and dideoxyinosine	DDI-false
diuretics e.g. triamterene , @DRUG$ , @DRUG$ supplements , or potassium-containing salt may lead to increases serum potassium .	DDI-false
Adverse Reactions to @DRUG$ : A review of the range 11 28 % ) of 501 patients treated containing regimens @DRUG$ experienced , atypical adverse .	DDI-false
Although this effect even when @DRUG$ @DRUG$ this did	DDI-effect
EM individuals treated or @DRUG$ the AUC atomoxetine is approximately to 8-fold Css , max 3- to @DRUG$ alone	DDI-false
EM individuals treated with paroxetine or @DRUG$ , AUC of @DRUG$ is approximately to 8-fold , about 3- to 4-fold greater than alone	DDI-mechanism
, lidocaine/quinidine , @DRUG$/acetaminophen , acid , , theophylline/acetaminophen , and .	DDI-false
induce CYP3A4 ( e.g. , @DRUG$ , phenytoin carbamazepine , , @DRUG$ or St.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
Higher of @DRUG$ ( 10(-8 ) 10(-6 M ) or ( 3 X 10(-8 ) - the @DRUG$.	DDI-effect
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy.	DDI-false
To the of chemotherapy plus HAART on clinical of patients with , HIV-NHL ) authors compared a of patients with treated the , @DRUG$ , prednisone ( CHOP chemotherapy regimen with a group of patients who with CHOP chemotherapy a i.e. , cyclophosphamide , @DRUG$ and antiretroviral .	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.	DDI-false
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions.	DDI-mechanism
Monoamine Oxidase and should administered with in patients being @DRUG$ @DRUG$ the of formoterol the cardiovascular system may potentiated these	DDI-false
concomitant @DRUG$ does affect the pharmacokinetics of either @DRUG$ .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
results that @DRUG$ and acetate , @DRUG$ and retinoids , may of prostate a modification and .	DDI-false
To evaluate chemotherapy plus HAART course with , systemic non-Hodgkin ( HIV-NHL , the authors compared group 24 patients who treated , @DRUG$ , vincristine , ( CHOP ) regimen plus HAART with of 80 patients CHOP a CHOP-like ( , , prednisone with vincristine @DRUG$ therapy	DDI-false
acetaminophen/theophylline, @DRUG$/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
of @DRUG$ containing epinephrine norepinephrine to patients receiving @DRUG$ phenothiazines produce prolonged hypertension .	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	DDI-effect
Hypotension Patients Patients @DRUG$ and in whom pressure initiation of therapy enalapril or	DDI-effect
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-false
@DRUG$, lidocaine, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
In shown that precipitation containing @DRUG$ mixed @DRUG$.	DDI-false
Concomitant @DRUG$ the for	DDI-mechanism
In a study , @DRUG$ administered to receiving	DDI-false
, @DRUG$ Diuretics : Concomitant with xanthine derivatives steroids , @DRUG$ may potentiate of   .	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To evaluate impact chemotherapy HAART the patients with HIV-related systemic , the group patients with HIV-NHL were the cyclophosphamide doxorubicin , @DRUG$ , and @DRUG$ ( ) HAART a group 80 who were CHOP chemotherapy CHOP-like regimen ( i.e. , doxorubicin teniposide prednisone with vincristine plus ) antiretroviral	DDI-false
@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
adjustment STRATTERA may be necessary when with CYP2D6 inhibitors , , @DRUG$ , and	DDI-false
Concurrent administration drugs possessing nephrotoxic e.g. , aminoglycosides indomethacin ) , e.g. @DRUG$ ) , ) or e.g. , methotrexate @DRUG$ ) PROLEUKIN may toxicity organ .	DDI-false
may increase the effect antihypertensive drugs , , @DRUG$ , @DRUG$ .	DDI-false
, Methylxanthines and @DRUG$ : Concomitant xanthine , steroids , possible hypokalemic @DRUG$	DDI-false
to cancer patients dose range led to a of @DRUG$ The of alternate-day of mg of @DRUG$ drug metabolism in patients	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Withdrawal @DRUG$ @DRUG$ requirement 50 % .	DDI-mechanism
acetaminophen/theophylline , phenobarbital/acetaminophen @DRUG$/valproic , @DRUG$/acetaminophen , and valproic acid/phenobarbital	DDI-false
Fenfluramine slightly antihypertensive , e.g. , @DRUG$	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
clinical the subjects treated concomitantly @DRUG$ and sedatives ( @DRUG$ ) , that of subjects taking placebo medications .	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient to maximal 5 to 7 days the initiation of @DRUG$ length of withdrawal .	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
acetaminophen/theophylline lidocaine/quinidine , @DRUG$/acetaminophen , acid , quinidine/@DRUG$ , , acid/phenobarbital	DDI-false
ibogaine 40 mg/kg , @DRUG$ ( 40 mg/kg intravenous of and self-administration of @DRUG$ nicotine in ;	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a @DRUG$) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
@DRUG$ ( spironolactone , triamterene , amiloride , or @DRUG$-containing lead significant in potassium	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
concomitant clinical safety in subjects treated with Acamprosate with , @DRUG$ @DRUG$ ( , or analgesics taking with these	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
acetaminophen/theophylline , acid , theophylline/acetaminophen , and	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Non-selective including , : Concomitant use @DRUG$ and @DRUG$ cause	DDI-effect
groups ; submitted to daily hydroalcoholic solutions @DRUG$ , @DRUG$ higher alcohols and acetaldehyde the same proportions as found fermented alcoholic beverages ;	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
of @DRUG$ containing epinephrine or to patients receiving monoamine oxidase , tricyclic antidepressants @DRUG$ severe hypotension or hypertension .	DDI-effect
Although @DRUG$ nor retinyl the of prostatic RPMI1640 @DRUG$ alone , modify effect of	DDI-false
unlike @DRUG$ @DRUG$ does affect a nondrug water .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	DDI-false
Coingestion of @DRUG$ phenobarbital and @DRUG$ with at to concentrations decreases the the target .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Dosage of @DRUG$ be CYP2D6 , fluoxetine and	DDI-advise
Drugs : Drugs as @DRUG$ , procainamide phenothiazines @DRUG$ , may be associated with prolongation an increased ventricular .	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide;	DDI-false
The oxidase of @DRUG$ may persist for substantial discontinuation of drug and mind when drug prescribed following @DRUG$.	DDI-false
Other Cardiovascular Agents Enalapril enalapril concomitantly with @DRUG$ @DRUG$ calcium-blocking agents prazosin and without of significant interactions .	DDI-false
intensity , uniformity and course of @DRUG$ secobarbital @DRUG$ , hydrate methaqualone systematically 16 patients therapy	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ on of @DRUG$.	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/valproic , @DRUG$/acetaminophen , and valproic	DDI-false
Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The effects of DCG-IV and @DRUG$ phencyclidine (@DRUG$)-induced and behavioral changes in	DDI-false
Cardiovascular Agents enalapril IV been used concomitantly adrenergic-blocking , methyldopa , , @DRUG$ @DRUG$ and digoxin without of clinically significant adverse interactions .	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ , @DRUG$ Diuretics : treatment with xanthine derivatives diuretics may of .	DDI-false
The effects of @DRUG$ and L-CCG-1 @DRUG$ (PCP)-induced behavioral changes in .	DDI-false
The of hypotensive enalapril or @DRUG$ can be by @DRUG$ or the salt prior to with or enalaprilat	DDI-effect
Quetiapine ( ' @DRUG$ ' ) newly @DRUG$ with efficacy treatment positive and negative schizophrenia	DDI-false
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
, time course of anticoagulant @DRUG$ , @DRUG$ , glutethimide chloral and were investigated in patients coumarin .	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
: @DRUG$ and @DRUG$ concomitantly adrenergic-blocking agents , nitrates , agents , hydralazine , prazosin digoxin evidence of clinically significant .	DDI-false
Anticoagulants including coumarin derivatives indandione , @DRUG$ @DRUG$ , and aspirin increase risk of administered concomitantly with	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Concurrent of possessing ( @DRUG$ , cytotoxic ( e.g. , @DRUG$ or hepatotoxic ( methotrexate asparaginase ) with PROLEUKIN may increase toxicity	DDI-false
Slow-channel calcium blockers, such as @DRUG$, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Cardiovascular Agents : @DRUG$ enalapril have concomitantly beta , @DRUG$ , nitrates , agents , hydralazine prazosin and of adverse interactions	DDI-false
acetaminophen/@DRUG$, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	DDI-false
Non-selective MAO inhibitors including , , and @DRUG$ : of L-tyrosine non-selective @DRUG$ may cause hypertension	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
of possessing nephrotoxic , indomethacin myelotoxic ( , , cardiotoxic e.g. , @DRUG$ ) or , methotrexate , @DRUG$ with PROLEUKIN organ	DDI-false
the impact on clinical patients with HIV-related , non-Hodgkin lymphoma HIV-NHL ) authors retrospectively a group of 24 who , , and prednisone CHOP chemotherapy plus HAART with group 80 with a CHOP-like regimen i.e. cyclophosphamide , doxorubicin , @DRUG$ with @DRUG$ bleomycin receiving antiretroviral therapy .	DDI-false
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior.	DDI-false
The , and time @DRUG$ interference by phenobarbital glutethimide , chloral methaqualone were 16 patients receiving @DRUG$ therapy .	DDI-false
Other Agents Enalapril @DRUG$ been beta , nitrates , calcium-blocking agents @DRUG$ , prazosin clinically significant	DDI-false
administration drugs ( e.g. @DRUG$ , @DRUG$ chemotherapy ( e.g. doxorubicin ) e.g. methotrexate asparaginase ) with PROLEUKIN may increase in these organ systems	DDI-false
, , , theophylline/acetaminophen , and valproic acid/phenobarbital	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
the of chemotherapy on the clinical course patients , non-Hodgkin lymphoma ( HIV-NHL ) the a group of 24 with HIV-NHL who were with the , doxorubicin and CHOP plus group 80 were treated CHOP-like regimen i.e. @DRUG$ @DRUG$ teniposide , prednisone with ) antiretroviral therapy .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$ including tranylcypromine sulfate , @DRUG$ , pargyline HC1 use L-tyrosine and non-selective cause hypertension .	DDI-false
such @DRUG$ , , , and @DRUG$ be with QT-interval an risk ventricular arrhythmia .	DDI-false
be with @DRUG$ ( @DRUG$	DDI-false
, lidocaine/@DRUG$ , , , , theophylline/acetaminophen valproic acid/phenobarbital .	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , @DRUG$/valproic , quinidine/lidocaine , and valproic	DDI-false
@DRUG$ Tricyclic Antidepressants @DRUG$ should be administered with extreme patients with inhibitors the action of on cardiovascular may be potentiated by these agents .	DDI-false
Concomitant @DRUG$ , @DRUG$ , and antiretroviral in patients with human virus-related ,	DDI-false
, additional interaction @DRUG$ and propranolol not demonstrated any effect @DRUG$ , administration a patient chronically resulted in no difference in of of relative to control .	DDI-false
@DRUG$ derivatives indandione derivatives , inhibitors @DRUG$ NSAIDs ) , and aspirin increase the of bleeding when ardeparin .	DDI-false
have been shown to reduce PROLEUKIN-induced effects including fever insufficiency hyperbilirubinemia , confusion , and , of these with may reduce effectiveness @DRUG$ be avoided other antihypertensives potentiate the hypotension seen	DDI-false
Both @DRUG$ and block release in the	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$, coexisting in the contents of alcoholic beverages.	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-false
adjustment of @DRUG$ when @DRUG$ fluoxetine and	DDI-advise
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
therefore, the use of @DRUG$ does not necessitate an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels.	DDI-false
Concomitant administration of @DRUG$ the of	DDI-effect
The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	DDI-mechanism
Acetaminophen, @DRUG$, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
derivatives , indandione @DRUG$ such as ( ) , and aspirin may of bleeding when concomitantly with @DRUG$.	DDI-effect
Warfarin: @DRUG$ enhances the effect of @DRUG$.	DDI-false
No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), @DRUG$ (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
These results suggest that dexamethasone acetate possibly @DRUG$ may regulate of by a modification of and @DRUG$.	DDI-effect
Slow-channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Nephrotoxicity reported following concomitant of @DRUG$ and @DRUG$.	DDI-effect
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Monoamine Inhibitors and Tricyclic : @DRUG$ be administered in patients treated oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on system be by .	DDI-false
on Diuretic Patients diuretics especially those whom diuretic was instituted , may occasionally experience an excessive reduction of blood after initiation @DRUG$	DDI-false
@DRUG$ @DRUG$ interaction .	DDI-int
In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	DDI-false
administration local anesthetic epinephrine or norepinephrine to receiving @DRUG$ tricyclic antidepressants or @DRUG$ may , prolonged or .	DDI-false
In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
@DRUG$ and glutethimide should not be administered to patients receiving @DRUG$.	DDI-advise
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, @DRUG$, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
both @DRUG$ , possibly glucocorticoids and @DRUG$ , may regulate the proliferation of epithelium by a of the of insulin and EGF	DDI-false
The of hypotensive effects can be minimized either the diuretic salt prior to of treatment with @DRUG$ @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
Anticoagulants , indandione , platelet aggregation @DRUG$ NSAIDs ) , may risk @DRUG$.	DDI-effect
To of chemotherapy HAART on of HIV-related , non-Hodgkin HIV-NHL ) the compared retrospectively of 24 patients with the @DRUG$ doxorubicin , prednisone ( CHOP chemotherapy regimen plus HAART a group 80 chemotherapy CHOP-like regimen ( , , doxorubicin , with vincristine bleomycin without receiving @DRUG$ therapy	DDI-false
Cardiovascular @DRUG$ enalapril IV have used concomitantly with agents methyldopa agents , prazosin @DRUG$ evidence of significant interactions .	DDI-false
lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic , , and acid/phenobarbital	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-effect
@DRUG$ and should not administered to patients receiving @DRUG$.	DDI-advise
, , phenobarbital/acetaminophen , , theophylline/acetaminophen and	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The intensity and time of anticoagulant phenobarbital , @DRUG$ and @DRUG$ investigated in 16 patients receiving coumarin	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Drugs Drugs , procainamide , @DRUG$ , @DRUG$ associated with QT-interval risk of ventricular .	DDI-false
have been shown to reduce @DRUG$-induced side including , , confusion and , concomitant administration of PROLEUKIN reduce the antitumor effectiveness of should be avoided Beta-blockers and other antihypertensives may potentiate	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Concurrent administration possessing ( , @DRUG$ , ) , ( , , cardiotoxic ( e.g. e.g. methotrexate , asparaginase effects with @DRUG$ may these organ .	DDI-effect
Other Cardiovascular Agents : Enalapril enalapril have been concomitantly with beta adrenergic-blocking agents , @DRUG$ @DRUG$ , prazosin evidence of clinically significant interactions	DDI-false
acetaminophen/theophylline , , phenobarbital/@DRUG$ , @DRUG$/acetaminophen acid/phenobarbital	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
MAO including @DRUG$ , @DRUG$ HC1 : Concomitant inhibitors may hypertension	DDI-false
@DRUG$ may drugs e.g. @DRUG$ , methyldopa , reserpine	DDI-effect
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-false
uniformity and course of by secobarbital @DRUG$ , @DRUG$ methaqualone systematically 16 patients receiving therapy	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ have been shown to reduce PROLEUKIN-induced fever , and dyspnea concomitant PROLEUKIN of PROLEUKIN thus should avoided 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	DDI-false
possibility of hypotensive effects or be either discontinuing @DRUG$ or increasing the salt intake to initiation of treatment enalapril or @DRUG$.	DDI-false
@DRUG$ had presence	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
@DRUG$ not used for inhaled @DRUG$.	DDI-false
Potassium-sparing diuretics @DRUG$ , @DRUG$ amiloride ) , , or may to increases serum potassium	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-advise
Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
and @DRUG$ be administered receiving	DDI-advise
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ , lidocaine phenobarbital , , @DRUG$ were added to pooled at therapeutic concentrations	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	DDI-false
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	DDI-false
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	DDI-effect
diuretics ( spironolactone @DRUG$ or amiloride ) , potassium or @DRUG$-containing salt substitutes may potassium	DDI-false
phenobarbital/@DRUG$ , quinidine/lidocaine theophylline/@DRUG$ , acid/phenobarbital .	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	DDI-effect
Other Drugs : such as , procainamide , @DRUG$ @DRUG$ associated prolongation risk of ventricular arrhythmia	DDI-false
use @DRUG$ eliminated by active may in plasma of @DRUG$.	DDI-mechanism
Therefore concomitant of psychotropic @DRUG$ , , @DRUG$ )	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
@DRUG$ @DRUG$ : treatment with xanthine , or diuretics potentiate a of	DDI-false
Concomitant cyclophosphamide @DRUG$ , and @DRUG$ active with human non-Hodgkin lymphoma .	DDI-false
The administration anesthetic solutions @DRUG$ to inhibitors , @DRUG$ severe prolonged .	DDI-effect
Drug/Laboratory Interactions @DRUG$ , including @DRUG$ , are to occasionally induce positive Coombs .	DDI-false
Moreover , additional interaction with @DRUG$ @DRUG$ demonstrated any effect plasma levels , a population receiving digoxin difference in of bioavailability digoxin relative control	DDI-false
Physiological oral @DRUG$ load constitutes the best tool for diagnosis of @DRUG$ deficiency and the first step of its treatment.	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	DDI-false
Other : Enalapril @DRUG$ have been used concomitantly , , nitrates , agents , @DRUG$ and digoxin of clinically significant adverse .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	DDI-false
@DRUG$ , @DRUG$ , plus therapy patients with immunodeficiency	DDI-false
Although glucocorticoids have been shown reduce PROLEUKIN-induced side effects including fever , , hyperbilirubinemia , dyspnea concomitant of these agents @DRUG$ may effectiveness of PROLEUKIN thus should be . Beta-blockers other may hypotension seen @DRUG$.	DDI-false
@DRUG$ slightly the of drugs , @DRUG$.	DDI-effect
( SH/DA ; SH/FA were daily treatment with solutions @DRUG$ , higher @DRUG$ and the as found in common distilled and fermented alcoholic beverages	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
acetaminophen/theophylline , , phenobarbital/valproic , , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Other Agents @DRUG$ IV @DRUG$ methyldopa nitrates , agents , without evidence of clinically adverse interactions	DDI-false
, , acid , quinidine/@DRUG$ , acid/phenobarbital .	DDI-false
of acetaminophen with @DRUG$ , phenobarbital with , @DRUG$ at toxic the binding of	DDI-false
These suggest that @DRUG$ retinyl , possibly other glucocorticoids , the proliferation dose-dependent modification @DRUG$ .	DDI-effect
Drugs such as quinidine @DRUG$ phenothiazines , @DRUG$ , antidepressants may be associated QT-interval and risk ventricular arrhythmia	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Therefore , interactions following administration psychotropic drugs @DRUG$ @DRUG$ , sedatives tranquilizers ) .	DDI-false
Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
inhibition during the @DRUG$ , @DRUG$	DDI-false
inhibitors @DRUG$ CYP2D6 to @DRUG$.	DDI-false
@DRUG$ coumarin derivatives , , @DRUG$ as nonsteroidal anti-inflammatory ( NSAIDs ) , aspirin when ardeparin	DDI-false
Dosage necessary , e.g. , @DRUG$ and	DDI-false
To the on with HIV-related , lymphoma ( HIV-NHL , authors compared group of 24 with who treated with the @DRUG$ , doxorubicin ( CHOP chemotherapy HAART with who were with chemotherapy or CHOP-like , @DRUG$ , and vincristine plus ) receiving therapy .	DDI-false
lidocaine/quinidine , phenobarbital/acetaminophen , acid , quinidine/lidocaine , and valproic	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ should to patients receiving @DRUG$ ( disulfiram , Wyeth-Ayerst Laboratories )	DDI-advise
suggest @DRUG$ has a narrower of actions and have a therapeutic	DDI-false
@DRUG$ ( 40 mg/kg ) @DRUG$ ( 40 mg/kg ) the self-administration of and and oral of ethanol in	DDI-false
Other Cardiovascular Agents Enalapril and IV with @DRUG$ , nitrates calcium-blocking , hydralazine @DRUG$ and digoxin without of clinically interactions .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
To evaluate of HAART on clinical course of patients , , lymphoma HIV-NHL ) the group 24 patients HIV-NHL who the doxorubicin ( CHOP HAART 80 patients treated with CHOP or a CHOP-like regimen ( i.e. , @DRUG$ teniposide , and prednisone vincristine @DRUG$ receiving antiretroviral	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	DDI-false
of @DRUG$ @DRUG$ acetaminophen , and acid with high to concentrations decreases binding of target .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ , Methylxanthines and : treatment with @DRUG$ or potentiate a possible  	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
impact chemotherapy HAART on the clinical course of patients HIV-related , systemic lymphoma HIV-NHL the compared a 24 with were cyclophosphamide , doxorubicin , , prednisone CHOP chemotherapy regimen HAART a group of 80 patients were treated with CHOP or regimen i.e. @DRUG$ , doxorubicin and with @DRUG$ without therapy	DDI-false
Fenfluramine of @DRUG$ e.g. @DRUG$.	DDI-false
Corticosteroids Methylxanthines @DRUG$ xanthine derivatives @DRUG$ or diuretics potentiate effect   beta2-agonists .	DDI-false
lidocaine @DRUG$ , @DRUG$ were pooled human at therapeutic concentrations .	DDI-false
@DRUG$, lidocaine, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Co-administration @DRUG$ Acamprosate produced 25 increase in AUC and a 33 increase in @DRUG$.	DDI-false
acetaminophen/theophylline , phenobarbital/valproic acid , quinidine/lidocaine , ,	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	DDI-effect
It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
While 18-MC @DRUG$ have similar for opioid and possibly nicotinic 18-MC much affinities @DRUG$ and , and 5-HT transporter .	DDI-false
neither @DRUG$ the proliferation prostatic in containing transferrin alone , they mitogenic effect @DRUG$ and .	DDI-effect
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
may effect of @DRUG$ , , @DRUG$ , methyldopa reserpine .	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
@DRUG$ ( @DRUG$ ) on 1,4,5-trisphosphate ( responses were studied rat marrow megakaryocytes with whole-cell in fura-2	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ may effect @DRUG$ , guanethidine , methyldopa , reserpine	DDI-effect
, lidocaine/quinidine phenobarbital/@DRUG$ , phenobarbital/valproic , valproic acid/phenobarbital .	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , , quinidine/lidocaine valproic acid/phenobarbital .	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Cardiovascular Enalapril and have been used concomitantly beta adrenergic-blocking agents methyldopa nitrates , calcium-blocking agents @DRUG$ , @DRUG$ significant interactions	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ such verapamil @DRUG$ nifedipine , inhibit platelet in vitro , intravascularly .	DDI-false
@DRUG$ and have similar kappa possibly receptors , @DRUG$ has much ibogaine for NMDA sigma-2 receptors , sodium channels , and the 5-HT .	DDI-false
interactions between and @DRUG$ or @DRUG$.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Potassium-sparing @DRUG$ triamterene , @DRUG$ ) supplements potassium-containing salt substitutes to serum	DDI-false
lidocaine/quinidine , , acid , quinidine/lidocaine , theophylline/acetaminophen .	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The uniformity of anticoagulant by @DRUG$ hydrate and @DRUG$ were investigated in coumarin .	DDI-false
Oxidase and Tricyclic should be in patients being with inhibitors @DRUG$ the of @DRUG$ on the cardiovascular may be potentiated by	DDI-false
, effects either warfarin times were observed involving of @DRUG$ @DRUG$.	DDI-false
@DRUG$/theophylline , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen and valproic acid/phenobarbital .	DDI-false
Similarly dialyzed @DRUG$ @DRUG$ , theophylline therapeutic concentrations serum and ethanol three concentrations in	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ ( ( 40 decreases the intravenous and @DRUG$ and oral ethanol in	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
ibogaine and @DRUG$ decrease extracellular of dopamine the nucleus , but @DRUG$ levels of accumbens	DDI-false
adjustment when with CYP2D6 , e.g. @DRUG$ , @DRUG$ , and quinidine	DDI-false
These that of @DRUG$ in beverages is enhanced by with its and @DRUG$ ;	DDI-effect
@DRUG$ and @DRUG$ : FORADIL should administered with being with or tricyclic the of on system be these .	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
phenobarbital @DRUG$ @DRUG$ and valproic were human at .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
and @DRUG$ similarly inhibit and @DRUG$- or of epithelium .	DDI-effect
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
Drugs that plasma that increase imatinib plasma concentrations Caution recommended when administering Gleevec inhibitors of , ketoconazole , @DRUG$ , @DRUG$ ) .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/@DRUG$, and valproic acid/phenobarbital.	DDI-false
, lidocaine/quinidine , @DRUG$/acetaminophen , quinidine/lidocaine , theophylline/acetaminophen	DDI-false
that may alter imatinib @DRUG$ plasma : Caution is recommended when administering with inhibitors of the family ( e.g. @DRUG$ , clarithromycin ) .	DDI-false
healthy with doses of followed a single dose @DRUG$ @DRUG$ clearance by significantly ( p 0.05 ) and AUC(0 - .	DDI-false
@DRUG$ : review the literature 12.6 % range 11 - ) 501 patients with various @DRUG$ containing subsequently radiographic media experienced acute , atypical adverse reactions	DDI-false
Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	DDI-mechanism
acetaminophen/theophylline, @DRUG$/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ and retinyl acetate similarly and stimulate @DRUG$- or insulin-induced prostatic .	DDI-effect
Drugs may alter @DRUG$ may imatinib plasma Caution is when administering ketoconazole , @DRUG$ erythromycin ,	DDI-false
occur administration drugs , , @DRUG$ , , @DRUG$	DDI-false
@DRUG$ with @DRUG$ phenobarbital with acetaminophen and valproic acid phenobarbital at high to the binding of drug .	DDI-effect
has following concomitant of @DRUG$ with antibiotics as @DRUG$.	DDI-effect
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Cardiovascular Agents : and used concomitantly with beta adrenergic-blocking , , @DRUG$ calcium-blocking , prazosin @DRUG$ adverse .	DDI-false
Other Agents @DRUG$ IV been used beta adrenergic-blocking agents , nitrates agents , @DRUG$ , and digoxin without clinically significant .	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
The possibility of with @DRUG$ or enalaprilat be minimized either the diuretic increasing the salt prior to of treatment with @DRUG$ or enalaprilat	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
a increase in to @DRUG$ @DRUG$ ketoconazole ( inhibitor ) .	DDI-false
effect rifampin the @DRUG$ patient to maximal to 7 the initiation rifampin and extended time after @DRUG$	DDI-false
@DRUG$ , 18-MC mg/kg ) decreases and cocaine and the oral of ethanol and @DRUG$ rats ;	DDI-false
, additional with niacin and have any effect on @DRUG$ plasma and patient population chronically receiving resulted in no difference in of of @DRUG$ control data	DDI-false
To evaluate the impact the course HIV-related , systemic non-Hodgkin ( HIV-NHL , authors a group of HIV-NHL treated cyclophosphamide , , , ) chemotherapy regimen a group of patients were with CHOP-like regimen ( i.e. cyclophosphamide doxorubicin , with @DRUG$ bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
dialyzed @DRUG$ theophylline , both alone at therapeutic concentrations in serum and with @DRUG$ three different concentrations in serum	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-false
Acetaminophen , @DRUG$ quinidine , theophylline and @DRUG$ were added to pooled human serum at therapeutic concentrations .	DDI-false
with theophylline @DRUG$ acetaminophen and @DRUG$ with at high to binding the .	DDI-false
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	DDI-mechanism
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
( dexamethasone , @DRUG$ , @DRUG$ or	DDI-false
Therefore , sodium is to patient receiving @DRUG$ , dosage @DRUG$ should be reduced prevent prolongation of the	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
apomorphine of diphenidol may decrease @DRUG$ to @DRUG$ treatment of poisoning	DDI-false
, phenobarbital/acetaminophen phenobarbital/@DRUG$ , and .	DDI-false
evaluate HAART on clinical of HIV-related systemic , the authors retrospectively group 24 patients were treated the @DRUG$ , vincristine , @DRUG$ chemotherapy regimen a of 80 were with CHOP chemotherapy or CHOP-like i.e. cyclophosphamide , teniposide , and prednisone vincristine receiving antiretroviral .	DDI-false
To of plus HAART on clinical course patients with HIV-related , systemic , non-Hodgkin lymphoma ( , of 24 with HIV-NHL who were treated vincristine and prednisone ) regimen patients with CHOP chemotherapy or a regimen ( i.e. , , and prednisone with @DRUG$ @DRUG$ ) receiving antiretroviral therapy .	DDI-false
@DRUG$ including derivatives indandione derivatives , aggregation inhibitors nonsteroidal NSAIDs @DRUG$ the risk of when administered with ardeparin	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
acquainted with clinical and paraclinical pattern of magnesium and between magnesium deficiency due to @DRUG$ intake which only requires physiological supplementation depletion dysregulation of the control mechanisms @DRUG$ requires more less regulation its causal .	DDI-false
Similarly dialyzed were @DRUG$ , and alone at therapeutic with @DRUG$ at three different concentrations serum .	DDI-false
Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	DDI-false
have been reported patients receiving combination regimens sequential dose and @DRUG$ , dacarbazine , cis-platinum , @DRUG$ and interferon-alfa .	DDI-false
results that @DRUG$ possibly other retinoids , regulate the proliferation prostate by modification of activity of insulin @DRUG$.	DDI-effect
Although shown side including fever , insufficiency , confusion , administration of with PROLEUKIN be avoided 12 @DRUG$ other antihypertensives hypotension	DDI-false
, , phenobarbital/@DRUG$ , phenobarbital/valproic , quinidine/lidocaine ,	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
( , ) @DRUG$ supplements @DRUG$-containing substitutes to in serum potassium .	DDI-false
@DRUG$ : @DRUG$ has in receiving lithium concomitantly drugs which elimination of sodium .	DDI-false
The of anesthetic containing @DRUG$ receiving @DRUG$ , produce severe , hypotension or .	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Administering @DRUG$ together with @DRUG$ (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.	DDI-effect
It therefore necessary to be well acquainted the and paraclinical pattern to discriminate @DRUG$ deficiency to intake requires oral physiological @DRUG$ a dysregulation control status more specific causal .	DDI-false
@DRUG$ administration to three cancer patients over a range mg to 2.2 dose-dependent inhibition of elimination.14 effect alternate-day of 0.25 mg @DRUG$ drug in MS is unknown	DDI-false
Like 40 mg/kg ) @DRUG$ 40 the intravenous self-administration morphine and @DRUG$ in	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
has administration @DRUG$ aminoglycoside antibiotics or @DRUG$	DDI-effect
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$/theophylline lidocaine/quinidine phenobarbital/acetaminophen , acid , valproic	DDI-false
lidocaine/quinidine , , acid , , and acid/phenobarbital	DDI-false
@DRUG$ been reduce side , renal insufficiency concomitant administration these of PROLEUKIN and thus should . Beta-blockers antihypertensives potentiate the hypotension with @DRUG$.	DDI-false
administration of local anesthetic containing epinephrine or to receiving , @DRUG$ or @DRUG$ produce severe hypotension	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	DDI-mechanism
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	DDI-false
when administering Gleevec CYP3A4 that a narrow window @DRUG$ @DRUG$ )	DDI-false
, , phenobarbital/valproic acid theophylline/acetaminophen and @DRUG$/phenobarbital .	DDI-false
@DRUG$ Antidepressants : FORADIL be with extreme in patients with @DRUG$ antidepressants because the of formoterol system may potentiated	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
Monoamine Inhibitors @DRUG$ be administered with extreme caution patients treated @DRUG$ because action cardiovascular system potentiated by these agents .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The administration @DRUG$ or @DRUG$ monoamine oxidase inhibitors tricyclic or may hypotension or hypertension	DDI-false
It therefore to be well with the paraclinical pattern deficit and between @DRUG$ deficiency due to an insufficient requires magnesium depletion related to dysregulation control mechanisms of @DRUG$ status more specific of its causal .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concurrent administration possessing nephrotoxic , , ( e.g. , cytotoxic chemotherapy , cardiotoxic ( e.g. @DRUG$ or , @DRUG$ asparaginase ) effects increase systems	DDI-false
suggest that and acetate , and other @DRUG$ and @DRUG$ may of epithelium by a dose-dependent modification the activity of .	DDI-false
Although neither @DRUG$ nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Concomitant @DRUG$, @DRUG$, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
It concluded @DRUG$ and @DRUG$ be in prothrombin	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
EM individuals treated paroxetine or fluoxetine , the AUC of @DRUG$ approximately 8-fold Css , to 4-fold greater than @DRUG$ alone .	DDI-false
@DRUG$ including @DRUG$ sulfate pargyline Concomitant use and non-selective inhibitors may cause .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
the results of these studies , it is that azithromycin be coadministered @DRUG$ and @DRUG$.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
drugs possessing nephrotoxic ( e.g. , aminoglycosides , , ( , @DRUG$ , cardiotoxic ( e.g. , @DRUG$ or ( asparaginase with PROLEUKIN increase toxicity in organ	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concomitant @DRUG$ doxorubicin , vincristine , and prednisone @DRUG$ therapy in patients immunodeficiency virus-related ,	DDI-false
may @DRUG$ plasma Drugs that concentrations is of the CYP3A4 ( @DRUG$ , erythromycin clarithromycin ) .	DDI-false
evaluate the of chemotherapy HAART course of patients with HIV-related ) authors compared retrospectively a of with were the @DRUG$ doxorubicin vincristine prednisone ( chemotherapy regimen plus HAART with a 80 patients who treated CHOP-like regimen , @DRUG$ , teniposide prednisone plus antiretroviral therapy	DDI-false
acetaminophen/theophylline lidocaine/@DRUG$ , phenobarbital/valproic acid , acid/@DRUG$.	DDI-false
This study demonstrated that the potent P450 @DRUG$ effect on the metabolism @DRUG$ resulting a in clearance to with DSM-IV-diagnosed , schizoaffective bipolar	DDI-mechanism
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$ derivatives aggregation inhibitors as nonsteroidal ( NSAIDs aspirin the bleeding concomitantly	DDI-effect
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other : the subjects with @DRUG$ , @DRUG$ and sedatives ( benzodiazepines ) , or analgesics to of subjects taking with these	DDI-false
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	DDI-false
impact of plus patients , systemic , the authors compared retrospectively of HIV-NHL the @DRUG$ vincristine , and ( CHOP ) regimen plus HAART of patients were chemotherapy a CHOP-like regimen i.e. , @DRUG$ , doxorubicin , , prednisone with vincristine bleomycin antiretroviral therapy	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-effect
Other : Enalapril and enalapril IV been with beta adrenergic-blocking agents , @DRUG$ , , calcium-blocking agents , hydralazine , and @DRUG$ without evidence of clinically adverse interactions	DDI-false
groups ; were daily treatment with synthetic solutions containing ethanol @DRUG$ @DRUG$ the same as found most	DDI-false
Anticoagulants including derivatives derivatives such as ( @DRUG$ ) and @DRUG$ may the risk of when administered concomitantly with	DDI-false
interactions could occur concomitant administration @DRUG$ e.g. , @DRUG$ , sedatives )	DDI-false
@DRUG$ and interact with administered @DRUG$ , the not clinically significant	DDI-int
Chloramphenicol to be to @DRUG$ , @DRUG$ based in studies time with enteric gram-negative bacilli .	DDI-false
Other Drugs as quinidine , @DRUG$ , @DRUG$ , QT-interval an risk of	DDI-false
Potassium-sparing diuretics ( e.g. @DRUG$ , amiloride , @DRUG$ supplements , salt substitutes may lead to significant increases in potassium .	DDI-false
Like mg/kg ) , @DRUG$ ( mg/kg the morphine @DRUG$ and the self-administration in	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
There are 3 types of indications: specific (for the treatment of some forms of @DRUG$ deficit i.e. acute), pharmacological (i.e. without alterations of @DRUG$ status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).	DDI-false
@DRUG$ displace phenytoin or @DRUG$ from their .	DDI-mechanism
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
The concomitant intake of and @DRUG$ does affect either or	DDI-false
Concurrent administration of drugs e.g. aminoglycosides ) , ( e.g. , @DRUG$ ) , cardiotoxic ( e.g. ) , @DRUG$ effects PROLEUKIN may toxicity in these .	DDI-false
intensity course of interference by @DRUG$ , , @DRUG$ investigated patients receiving coumarin .	DDI-false
taking @DRUG$ concomitantly with @DRUG$ more reported weight loss , with patients taking medication .	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
, theophylline/@DRUG$ , and valproic .	DDI-false
the of metabotropic receptor ) agonists , @DRUG$ , behavioral by @DRUG$ were found	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-false
Similarly dialyzed were @DRUG$, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and @DRUG$/phenobarbital.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Coingestion of acetaminophen with , @DRUG$ @DRUG$ phenobarbital high concentrations decreases the target .	DDI-effect
is necessary be well acquainted with paraclinical of deficit and to discriminate due to an intake requires @DRUG$ depletion a dysregulation @DRUG$ requires more or specific regulation of .	DDI-false
In pharmacological novel reaction temazepam ( @DRUG$ ) and @DRUG$ conditions to found in vivo , resulting a product	DDI-false
Coingestion of @DRUG$ with theophylline, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In treated @DRUG$ fluoxetine , AUC of atomoxetine approximately 6- 8-fold and max about to than @DRUG$ alone .	DDI-false
@DRUG$ , , platelet aggregation inhibitors such nonsteroidal anti-inflammatory drugs @DRUG$ and aspirin increase risk of bleeding administered .	DDI-false
evaluate the impact of chemotherapy the clinical HIV-related , systemic ( HIV-NHL ) , authors compared a of with who treated @DRUG$ @DRUG$ and CHOP ) chemotherapy regimen plus HAART with group 80 patients treated with CHOP or a CHOP-like cyclophosphamide , doxorubicin , , and vincristine plus without antiretroviral therapy	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , theophylline/acetaminophen , and acid/phenobarbital .	DDI-false
Other Drugs Drugs quinidine disopyramide procainamide , @DRUG$ @DRUG$ , be and risk .	DDI-false
acetaminophen/theophylline , phenobarbital/@DRUG$ , phenobarbital/@DRUG$ quinidine/lidocaine theophylline/acetaminophen , and .	DDI-false
and Diuretics treatment with derivatives , @DRUG$ , potentiate possible hypokalemic effect of @DRUG$	DDI-effect
@DRUG$ @DRUG$ not to patients receiving drugs .	DDI-false
Diuretic Therapy : Patients on @DRUG$ and those whom diuretic therapy recently instituted , may occasionally excessive reduction blood pressure after initiation of therapy with @DRUG$ or .	DDI-effect
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , , quinidine/lidocaine , valproic	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
interactions occur concomitant of @DRUG$ e.g. narcotics , analgesics , antiemetics @DRUG$ )	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	DDI-false
The effects of @DRUG$ (RR) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
The pressure effect @DRUG$ tended be in patients on @DRUG$ on no other therapy .	DDI-effect
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	DDI-false
@DRUG$ increase the of drugs , guanethidine @DRUG$ reserpine .	DDI-effect
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Similarly dialyzed were phenobarbital, @DRUG$, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/@DRUG$ quinidine/lidocaine , acid/phenobarbital .	DDI-false
Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
effects @DRUG$ prothrombin were a study involving concomitant of @DRUG$ fluvastatin .	DDI-false
Cardiovascular Agents Enalapril @DRUG$ methyldopa @DRUG$ hydralazine , digoxin of clinically significant adverse interactions	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-mechanism
@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	DDI-advise
Acetaminophen, lidocaine, phenobarbital, @DRUG$, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Other Drugs , @DRUG$ procainamide , @DRUG$ , and associated QT-interval and increased of ventricular arrhythmia .	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	DDI-false
reported in receiving combination containing sequential high @DRUG$ cis-platinum and	DDI-false
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
@DRUG$ increase other CYP3A4 ( e.g. , @DRUG$ certain reductase inhibitors , . ) .	DDI-mechanism
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Two ( SH/DA SH/FA ) synthetic solutions containing ethanol , methanol higher @DRUG$ and @DRUG$ same proportions as found in common distilled and alcoholic beverages	DDI-false
@DRUG$     @DRUG$ antagonism	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
the of HAART on the course of with , ( HIV-NHL ) , compared a group of who were treated the , , regimen plus a of 80 patients who treated with CHOP CHOP-like ( , @DRUG$ , prednisone with plus bleomycin ) receiving @DRUG$	DDI-false
Because @DRUG$ is metabolized by and , anticoagulation	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
therapies In clinical , safety profile subjects treated @DRUG$ with and @DRUG$ ) or non-opioid analgesics similar to of subjects concomitant medications	DDI-false
@DRUG$ an resin , has considerable in lowering and extent @DRUG$ .	DDI-mechanism
@DRUG$ administered caution to ( @DRUG$ Wyeth-Ayerst Laboratories ) .	DDI-advise
had no significant impact on and of @DRUG$ , significantly the @DRUG$ by and increased intracellular exposure phosphorylated zidovudine by 110	DDI-false
Corticosteroids @DRUG$ @DRUG$ Concomitant derivatives , steroids or may a possible hypokalemic beta2-agonists .	DDI-false
Other Cardiovascular : Enalapril IV been used with beta adrenergic-blocking agents , , @DRUG$ , calcium-blocking @DRUG$ and evidence of	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Therefore @DRUG$ is a warfarin , dosage @DRUG$ to excessive prothrombin .	DDI-false
@DRUG$ such @DRUG$ , diltiazem inhibit , and decrease platelet	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients.	DDI-false
To of the of patients lymphoma ) , the compared retrospectively who treated the doxorubicin , @DRUG$ , ( CHOP ) chemotherapy plus HAART with a 80 patients who CHOP chemotherapy or a CHOP-like ( i.e. , teniposide , and prednisone plus ) without receiving @DRUG$ therapy .	DDI-false
@DRUG$    @DRUG$ antagonism	DDI-false
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability.	DDI-mechanism
It therefore necessary be acquainted with the clinical paraclinical pattern magnesium and to between @DRUG$ to insufficient @DRUG$ intake requires oral physiological supplementation and depletion related of the of magnesium requires or specific of its	DDI-false
@DRUG$ ('@DRUG$') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
glucocorticoids been reduce PROLEUKIN-induced fever , renal insufficiency , hyperbilirubinemia , dyspnea administration agents PROLEUKIN reduce the antitumor of PROLEUKIN be avoided . 12 @DRUG$ and other @DRUG$ may the seen with PROLEUKIN .	DDI-false
To evaluate the impact chemotherapy HAART clinical of , systemic lymphoma ( HIV-NHL , compared retrospectively a group 24 with were treated cyclophosphamide , vincristine @DRUG$ ) chemotherapy regimen HAART of 80 with CHOP chemotherapy or a regimen i.e. , @DRUG$ , doxorubicin and without receiving antiretroviral therapy .	DDI-false
To evaluate the impact the course of HIV-related systemic ) the authors group 24 who were treated doxorubicin @DRUG$ and CHOP ) chemotherapy HAART of who CHOP a CHOP-like ( i.e. , doxorubicin @DRUG$ with plus bleomycin without antiretroviral therapy	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
pressure effect of to be greater in patients @DRUG$ patients no @DRUG$ therapy	DDI-false
Agents and enalapril have been used beta adrenergic-blocking agents , methyldopa @DRUG$ , , hydralazine @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	DDI-false
- @DRUG$ may decrease @DRUG$ to in the treatment of poisoning	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
ibogaine ( 40 mg/kg , 18-MC 40 mg/kg decreases the intravenous of morphine cocaine and the oral @DRUG$ @DRUG$ rats	DDI-false
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants.	DDI-false
@DRUG$ does not affect serum @DRUG$ levels.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	DDI-false
acetaminophen/theophylline , @DRUG$/@DRUG$ , phenobarbital/valproic , acid/phenobarbital .	DDI-false
Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;	DDI-false
Co-medications induce CYP3A4 , @DRUG$ , , @DRUG$ , phenobarbital St.	DDI-false
concomitant therapies clinical , safety in treated Acamprosate anxiolytics , @DRUG$ ( including or @DRUG$ similar to of with these concomitant	DDI-false
acetaminophen/theophylline lidocaine/quinidine @DRUG$/acetaminophen , , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
of phenytoin 40 mg @DRUG$ tablets in the @DRUG$ to	DDI-false
To evaluate the impact chemotherapy on course of with , , ( HIV-NHL the compared retrospectively group 24 with HIV-NHL with the cyclophosphamide doxorubicin , , and ( ) chemotherapy plus a of patients who were with CHOP or a CHOP-like ( i.e. cyclophosphamide , , teniposide plus @DRUG$ ) receiving @DRUG$	DDI-false
@DRUG$ in .	DDI-effect
of major @DRUG$ co-administration @DRUG$.	DDI-false
Cardiovascular : Enalapril and enalapril IV beta agents , nitrates , @DRUG$ , , @DRUG$ of clinically adverse	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.	DDI-false
@DRUG$ @DRUG$	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Nephrotoxicity been administration of or potent @DRUG$ such as	DDI-false
: In trials , with @DRUG$ , sedatives ( @DRUG$ ) or analgesics was similar that of subjects placebo these medications	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
phenobarbital/acetaminophen , , @DRUG$/lidocaine and valproic acid/phenobarbital .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
Careful is required when @DRUG$ is with	DDI-advise
Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	DDI-effect
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
It is necessary be with and and discriminate magnesium deficiency due an @DRUG$ which oral physiological supplementation and @DRUG$ depletion to mechanisms of status which specific of dysregulation	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Agents Renin Release : The antihypertensive @DRUG$ is augmented @DRUG$ cause renin e.g. , ) .	DDI-effect
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
( , , @DRUG$ ) potassium , or salt substitutes significant in .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	DDI-false
is necessary well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit discriminate between magnesium deficiency @DRUG$ which only oral supplementation magnesium depletion related to a dysregulation of control mechanisms magnesium which more or less specific of	DDI-false
MAO including @DRUG$ @DRUG$ and pargyline HC1 Concomitant of non-selective hypertension	DDI-false
@DRUG$, such as @DRUG$, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$ and Diuretics : Concomitant treatment with derivatives or diuretics may potentiate a possible effect of @DRUG$	DDI-false
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/@DRUG$.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	DDI-false
@DRUG$ ' Seroquel ) @DRUG$ with efficacy treatment positive and negative symptoms .	DDI-false
evaluate the chemotherapy plus on course of patients , systemic , compared group with who with the @DRUG$ @DRUG$ , , and ( CHOP HAART with a group 80 were chemotherapy ( cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine bleomycin without antiretroviral therapy	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
evaluate the impact on with HIV-related systemic non-Hodgkin lymphoma ( ) , compared retrospectively group of 24 with who were treated cyclophosphamide @DRUG$ , @DRUG$ , prednisone ) regimen patients who were with chemotherapy or regimen i.e. cyclophosphamide , vincristine plus ) receiving therapy .	DDI-false
@DRUG$ ( amiloride ) , @DRUG$ , substitutes may to significant potassium .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The @DRUG$ subjects with of azithromycin n 7 ) to mg/day [ n = 5 ] for Days 8 of 100 , five times/day of	DDI-false
acetaminophen/theophylline , , @DRUG$/acetaminophen , , quinidine/lidocaine acid/phenobarbital .	DDI-false
Concurrent nephrotoxic ( e.g. , @DRUG$ , ) ( cytotoxic chemotherapy ) , e.g. or hepatotoxic @DRUG$ ) effects PROLEUKIN may these organ systems .	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	DDI-advise
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
To evaluate impact of HAART the clinical course patients , systemic , lymphoma , authors compared retrospectively a group of patients HIV-NHL who were treated , ( CHOP chemotherapy plus a group who treated CHOP chemotherapy or regimen doxorubicin teniposide and @DRUG$ vincristine @DRUG$ ) without receiving antiretroviral .	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	DDI-effect
@DRUG$ @DRUG$ to approved and has been studied in humans since	DDI-false
, @DRUG$/@DRUG$ phenobarbital/valproic , theophylline/acetaminophen and acid/phenobarbital .	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
, lidocaine/quinidine phenobarbital/acetaminophen , quinidine/@DRUG$ , , valproic acid/@DRUG$.	DDI-false
( ii ) the @DRUG$ were efficiently by added the major membrane , the effects @DRUG$ inhibited ergosterol , membrane in yeast .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ , @DRUG$ , theophylline , valproic acid were added human serum concentrations .	DDI-false
@DRUG$ @DRUG$ interact with orally anticoagulant , is not .	DDI-false
Cardiovascular Agents enalapril been used concomitantly @DRUG$ , , nitrates calcium-blocking agents hydralazine , and @DRUG$ evidence of clinically significant adverse interactions	DDI-false
Drugs : such quinidine , @DRUG$ @DRUG$ , and tricyclic may be with QT-interval prolongation	DDI-false
lidocaine/@DRUG$ , , , , acid/phenobarbital .	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Other : @DRUG$ concomitantly with @DRUG$ , and ( including benzodiazepines ) , or analgesics that of with these concomitant	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	DDI-false
following eight target drug combinations : @DRUG$/@DRUG$.	DDI-false
, @DRUG$ stimulated not inhibit the @DRUG$.	DDI-effect
Anticoagulant inhibition was observed during the administration of @DRUG$, secobarbital and @DRUG$;	DDI-false
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Concurrent administration of drugs possessing aminoglycosides , ) ( e.g. cytotoxic ) , cardiotoxic ( e.g. doxorubicin or e.g. @DRUG$ effects @DRUG$ toxicity in these organ .	DDI-effect
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-false
Delayed Adverse Reactions to Contrast A review the that ( range 11 % ) patients various @DRUG$ containing were subsequently administered @DRUG$ , reactions	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The possibility of or @DRUG$ be discontinuing the diuretic increasing the prior to of with or	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	DDI-false
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
intensity , by @DRUG$ glutethimide @DRUG$ in patients receiving coumarin therapy	DDI-false
Drugs may concentrations that may imatinib plasma is when administering @DRUG$ of the CYP3A4 ( e.g. , , @DRUG$	DDI-advise
Both toxicity @DRUG$ therapeutic value of @DRUG$ rationalized following observations i polyene showed on cells ;	DDI-false
have been shown to reduce PROLEUKIN-induced side including , renal insufficiency , dyspnea concomitant these agents with PROLEUKIN may the and thus should avoided 12 Beta-blockers @DRUG$ potentiate the hypotension @DRUG$.	DDI-effect
of @DRUG$ on @DRUG$ studied rat bone with the recording with microfluorometry	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Pretreatment of megakaryocytes with extracellular @DRUG$ (50 microM) also inhibited @DRUG$-induced responses.	DDI-effect
Other therapies clinical , the profile subjects with @DRUG$ @DRUG$ and sedatives ( including ) , or non-opioid was similar to that of taking placebo with medications	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Corticosteroids , Methylxanthines Concomitant with xanthine steroids , @DRUG$ potentiate a hypokalemic effect   @DRUG$	DDI-effect
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously.	DDI-mechanism
have in patients receiving combination sequential high dose @DRUG$ and antineoplastic , , dacarbazine cis-platinum @DRUG$ and interferon-alfa	DDI-effect
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
@DRUG$ had impact the Cmax @DRUG$ significantly the zidovudine tmax intracellular exposure to phosphorylated by %	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine.	DDI-false
Concurrent administration of nephrotoxic ( e.g. , indomethacin ) ( e.g. , @DRUG$ ( , ) or hepatotoxic ( , methotrexate , @DRUG$ increase organ .	DDI-effect
suggest both dexamethasone @DRUG$ and possibly and retinoids may the proliferation prostate a modification of the @DRUG$ and	DDI-effect
Moreover , additional any on levels to patient chronically receiving @DRUG$ in no of @DRUG$ relative data	DDI-false
@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-effect
To the impact clinical with systemic , non-Hodgkin HIV-NHL ) compared a group of HIV-NHL treated cyclophosphamide doxorubicin and @DRUG$ ) HAART 80 who treated CHOP chemotherapy or a ( i.e. , doxorubicin , , and @DRUG$ with plus ) receiving antiretroviral .	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
( ; ) were submitted daily treatment with synthetic containing @DRUG$ methanol , higher @DRUG$ and acetaldehyde the same proportions as found most common and alcoholic ;	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
The intake alcohol and does not affect the of either @DRUG$	DDI-false
that induce ( @DRUG$ , @DRUG$ carbamazepine	DDI-false
could occur @DRUG$ ( narcotics , , @DRUG$ , tranquilizers	DDI-false
evaluate of chemotherapy HAART the clinical of patients systemic , ( HIV-NHL ) the authors compared a with HIV-NHL who were with @DRUG$ vincristine and CHOP ) chemotherapy regimen plus HAART a patients were with or regimen cyclophosphamide teniposide , and @DRUG$ with plus bleomycin ) receiving therapy	DDI-false
, , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , , and .	DDI-false
Like ( 40 mg/kg ( 40 mg/kg ) self-administration of @DRUG$ @DRUG$ and the oral of ethanol nicotine in rats ;	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Although glucocorticoids been side effects fever insufficiency , , , and dyspnea agents with @DRUG$ of PROLEUKIN and thus should be avoided @DRUG$ other antihypertensives potentiate seen with PROLEUKIN	DDI-false
Slow-channel blockers @DRUG$ , diltiazem and @DRUG$ inhibit platelet activation , and decrease platelet adhesion	DDI-false
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$ ( @DRUG$ ) measuring locomotor activity and stereotyped	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Both @DRUG$ @DRUG$ levels but only ibogaine increases levels of serotonin the nucleus accumbens .	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	DDI-false
Moreover, the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
The the formulation @DRUG$ was affected administered minutes following an	DDI-false
The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
, @DRUG$ , and prednisone chemotherapy plus @DRUG$ therapy patients human immunodeficiency virus-related non-Hodgkin lymphoma	DDI-false
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ for animal cells.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
the of @DRUG$ with @DRUG$ .	DDI-advise
acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
To evaluate the of chemotherapy plus on the course of patients HIV-related systemic , lymphoma ( ) , retrospectively group 24 patients with with , , vincristine ( CHOP chemotherapy a of who treated with CHOP a , cyclophosphamide doxorubicin , @DRUG$ and @DRUG$ vincristine plus ) receiving antiretroviral therapy .	DDI-false
acetaminophen/theophylline , , , phenobarbital/@DRUG$ , quinidine/lidocaine , and valproic acid/phenobarbital	DDI-false
lidocaine/quinidine , ,	DDI-false
Concurrent administration drugs nephrotoxic e.g. , aminoglycosides , @DRUG$ ) , myelotoxic ( , @DRUG$ chemotherapy ( e.g. , doxorubicin or hepatotoxic ( asparaginase effects with PROLEUKIN increase in these organ systems	DDI-false
It is the currently available @DRUG$ ( @DRUG$ , pravastatin ) to unique biopharmaceutical properties to of this .	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To impact chemotherapy plus HAART clinical of HIV-related ( HIV-NHL the retrospectively a 24 HIV-NHL were the , @DRUG$ vincristine and ( ) chemotherapy regimen HAART a group patients a ( , , @DRUG$ , teniposide and ) without antiretroviral therapy	DDI-false
Hypersensitivity combination containing sequential high dose PROLEUKIN and @DRUG$ specifically @DRUG$ and	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Monoamine and Tricyclic : FORADIL should with caution patients being with @DRUG$ or tricyclic antidepressants because of @DRUG$ cardiovascular system by	DDI-false
Although glucocorticoids been shown reduce effects , renal and dyspnea , of these with PROLEUKIN may the antitumor PROLEUKIN and be . @DRUG$ may potentiate hypotension seen	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
nor @DRUG$ affected the of in RPMI1640 @DRUG$ modify the and insulin	DDI-false
Non-selective inhibitors including , @DRUG$ , and pargyline HC1 : Concomitant use of non-selective @DRUG$ cause .	DDI-false
Similarly phenobarbital , @DRUG$ @DRUG$ , both in serum with at three concentrations in	DDI-false
Other Cardiovascular : @DRUG$ IV have been with adrenergic-blocking agents @DRUG$ , nitrates agents hydralazine and digoxin of adverse	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Hypersensitivity reported in receiving combination regimens containing high dose @DRUG$ and agents specifically , cis-platinum tamoxifen and @DRUG$.	DDI-effect
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-false
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
Other Drugs as disopyramide , @DRUG$ , phenothiazines @DRUG$ and tricyclic may be QT-interval prolongation and an of ventricular arrhythmia	DDI-false
ibogaine 40 mg/kg ) 18-MC 40 ) decreases the self-administration of morphine and @DRUG$ and the @DRUG$ in ;	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	DDI-false
The intensity uniformity anticoagulant by @DRUG$ , secobarbital , glutethimide , chloral and methaqualone systematically investigated in receiving @DRUG$ .	DDI-false
@DRUG$ , @DRUG$ , phenobarbital quinidine acid were to human at therapeutic concentrations	DDI-false
, lidocaine/quinidine , phenobarbital/valproic acid quinidine/lidocaine , theophylline/acetaminophen	DDI-false
including coumarin derivatives and @DRUG$ such nonsteroidal anti-inflammatory ( , @DRUG$ risk bleeding administered concomitantly with .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
This study demonstrated that the potent cytochrome P450 enzyme-inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.	DDI-mechanism
of who have @DRUG$ should be alerted to the general asthma especially of therapy @DRUG$.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Cardiovascular Agents : and enalapril have been used concomitantly with @DRUG$ @DRUG$ , agents , without evidence of clinically significant adverse	DDI-false
of @DRUG$ atenolol than patients on no @DRUG$ therapy	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
intensity uniformity of anticoagulant , secobarbital , , and @DRUG$ systematically in receiving @DRUG$ .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
The warfarin requirement of our to be maximal to the initiation @DRUG$ and extended a similar time @DRUG$ withdrawal .	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
The red ( @DRUG$ inositol 1,4,5-trisphosphate studied the technique in combination fura-2 microfluorometry .	DDI-false
oral @DRUG$ load constitutes the best tool for of @DRUG$ deficiency step of its .	DDI-false
@DRUG$ on steady-state of	DDI-false
Like 40 mg/kg decreases intravenous @DRUG$ and cocaine oral self-administration of @DRUG$ and ;	DDI-false
@DRUG$ , doxorubicin , , and @DRUG$ active antiretroviral immunodeficiency virus-related non-Hodgkin lymphoma	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	DDI-false
acetaminophen/theophylline phenobarbital/valproic acid , quinidine/lidocaine @DRUG$/acetaminophen acid/phenobarbital	DDI-false
Anticoagulants including coumarin derivatives indandione aggregation such @DRUG$ ) , and aspirin increase risk of bleeding	DDI-effect
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/acetaminophen phenobarbital/valproic , quinidine/lidocaine , theophylline/@DRUG$ , and valproic	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
, , phenobarbital/valproic , quinidine/@DRUG$ , , and acid/phenobarbital	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
, interaction studies niacin @DRUG$ have any @DRUG$ plasma levels , population receiving digoxin resulted in the to .	DDI-false
epithelium proliferates a defined medium consisting of basal containing @DRUG$ ( 1 , EGF ( 10 @DRUG$ ( 3.7 micrograms/ml 0.1 IU/ml	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	DDI-effect
@DRUG$ and @DRUG$ block morphine-induced nicotine-induced release the nucleus accumbens ;	DDI-false
, as , @DRUG$ @DRUG$ inhibit activation in , platelet intravascularly	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ will plasmaconcentration of other e.g. triazolo-benzodiazepines , dihydropyridine blockers , @DRUG$ , etc ) .	DDI-mechanism
Prostatic epithelium in a defined medium consisting of @DRUG$ ( 1 microgram/ml ) , @DRUG$ 10 ng/ml insulin 3.7 micrograms/ml IU/ml	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Similarly dialyzed were phenobarbital, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
the of metabotropic ( mGluR ) , @DRUG$ L-CCG-1 on above changes induced by @DRUG$ were	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
that may imatinib plasma concentrations Drugs increase @DRUG$ is administering inhibitors CYP3A4 e.g. , ketoconazole itraconazole @DRUG$ , clarithromycin .	DDI-false
The effects @DRUG$ and L-CCG-1 upon	DDI-false
Agents Renin : The effect @DRUG$ @DRUG$ IV agents that release ( , diuretics .	DDI-false
@DRUG$ with @DRUG$ a 25 % in AUC a 33 % in the of acamprosate	DDI-mechanism
To chemotherapy plus HAART on the course of patients HIV-related , systemic , non-Hodgkin ) the of patients with with @DRUG$ , vincristine , and ( CHOP plus HAART with of patients who were treated with regimen ( i.e. @DRUG$ , prednisone with vincristine plus ) receiving antiretroviral .	DDI-false
@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	DDI-false
Co-medications that ( e.g. , phenytoin carbamazepine , @DRUG$ @DRUG$ St.	DDI-false
Other Agents @DRUG$ and IV with @DRUG$ , , hydralazine , evidence of significant adverse	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	DDI-false
acetaminophen/theophylline lidocaine/quinidine phenobarbital/@DRUG$ @DRUG$/valproic acid , quinidine/lidocaine , , and acid/phenobarbital	DDI-false
@DRUG$ phenobarbital , theophylline and @DRUG$ to at .	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
results suggest both acetate , possibly @DRUG$ and the proliferation epithelium modification of of	DDI-effect
Inhibitors @DRUG$ should be in being with @DRUG$ or tricyclic because formoterol the cardiovascular be potentiated these agents	DDI-advise
, lidocaine/quinidine phenobarbital/acetaminophen acid , , valproic	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In addition , we shown that @DRUG$ useful tool which examine responses of megakaryocytes	DDI-false
administration of possessing ( e.g. , , @DRUG$ e.g. cytotoxic chemotherapy , cardiotoxic ( doxorubicin hepatotoxic ( e.g. @DRUG$ ) effects increase toxicity organ systems .	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ norepinephrine to @DRUG$ antidepressants may produce prolonged hypotension	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Agents Enalapril and @DRUG$ been beta adrenergic-blocking methyldopa nitrates , , prazosin and @DRUG$ without clinically significant adverse .	DDI-false
Agents Renin : The effect @DRUG$ by antihypertensive agents renin release ( e.g. , @DRUG$ .	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
There types of indications for the of @DRUG$ deficit ) , i.e. without alterations @DRUG$ ) -- complications ) .	DDI-false
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.	DDI-false
Both the toxicity of filipin and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	DDI-false
is structurally the other currently available reductase inhibitors ( lovastatin @DRUG$ @DRUG$ ) to properties to of this .	DDI-false
acetaminophen/theophylline , , @DRUG$/valproic acid theophylline/@DRUG$ and valproic	DDI-false
Although have reduce PROLEUKIN-induced , and dyspnea agents with @DRUG$ may reduce the of should be avoided other @DRUG$ may potentiate hypotension with .	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
acetaminophen/theophylline lidocaine/quinidine , and	DDI-false
To impact of chemotherapy HAART on course with , non-Hodgkin HIV-NHL ) , the compared a of with treated cyclophosphamide , , and @DRUG$ CHOP ) chemotherapy plus group who were with chemotherapy or CHOP-like regimen ( i.e. cyclophosphamide teniposide and prednisone @DRUG$ plus bleomycin ) without antiretroviral therapy	DDI-false
To evaluate the impact of plus the clinical course with HIV-related , systemic non-Hodgkin , the authors compared a 24 patients HIV-NHL were treated with cyclophosphamide doxorubicin , @DRUG$ prednisone regimen with a group 80 were treated with or ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ vincristine plus bleomycin )	DDI-false
In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ , phenobarbital , @DRUG$ , , valproic acid were added to pooled human serum therapeutic .	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found.	DDI-false
acetaminophen/theophylline @DRUG$/quinidine phenobarbital/acetaminophen phenobarbital/valproic @DRUG$/lidocaine and valproic .	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	DDI-effect
The effects of red ( on @DRUG$ responses studied bone marrow megakaryocytes with technique in with microfluorometry .	DDI-false
This be mediated @DRUG$ enzymes , the of	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Cardiovascular : @DRUG$ have been used with beta adrenergic-blocking agents , methyldopa , , @DRUG$ , prazosin and digoxin of significant adverse interactions .	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
effect of @DRUG$ on @DRUG$ requirement our be 5 to 7 after of similar time after rifampin withdrawal .	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
@DRUG$ , and xanthine , or @DRUG$ may potentiate effect of  	DDI-false
of , @DRUG$ acetaminophen , and @DRUG$ to decreases binding of target drug	DDI-false
lidocaine/quinidine acid , , theophylline/acetaminophen acid/phenobarbital	DDI-false
Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-mechanism
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
plus HAART on the of patients with , non-Hodgkin HIV-NHL ) , the a of 24 who were cyclophosphamide doxorubicin , @DRUG$ ( ) chemotherapy regimen plus HAART with a group 80 patients who were treated CHOP or a CHOP-like ( , , doxorubicin and with @DRUG$ receiving therapy .	DDI-false
Like ibogaine ( @DRUG$ ( 40 intravenous @DRUG$ cocaine and oral self-administration ethanol and nicotine in	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
possibility of hypotensive or @DRUG$ can be minimized discontinuing or increasing the salt prior to initiation of with @DRUG$ enalaprilat	DDI-false
benzodiazepines a family of @DRUG$ @DRUG$.	DDI-false
To evaluate impact chemotherapy plus HAART of , lymphoma ( HIV-NHL , the authors compared retrospectively a of 24 patients with HIV-NHL who were treated the @DRUG$ , and ( CHOP ) chemotherapy plus with group of were CHOP or a CHOP-like regimen ( i.e. , teniposide prednisone @DRUG$ plus bleomycin without receiving antiretroviral	DDI-false
@DRUG$, such as verapamil, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	DDI-false
, and time course secobarbital @DRUG$ chloral and @DRUG$ were 16 patients receiving coumarin	DDI-false
Drugs that may plasma concentrations Drugs that may increase imatinib concentrations : recommended when administering @DRUG$ inhibitors of family ( e.g. , @DRUG$ erythromycin ,	DDI-advise
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis.	DDI-mechanism
Concomitant cyclophosphamide , @DRUG$ , @DRUG$ , and chemotherapy plus highly active with human , lymphoma .	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
Other such as @DRUG$ , @DRUG$ procainamide phenothiazines , and tricyclic associated with QT-interval prolongation an ventricular .	DDI-false
should be @DRUG$ given conjunction with	DDI-advise
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
It therefore to be acquainted with clinical paraclinical of @DRUG$ deficit and to discriminate magnesium deficiency to an which requires oral physiological supplementation and a dysregulation the of @DRUG$ specific	DDI-false
acetaminophen/theophylline lidocaine/quinidine , , valproic .	DDI-false
Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-advise
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
suggest both @DRUG$ and @DRUG$ , may prostate modification of the and EGF .	DDI-false
@DRUG$ @DRUG$ enhances effect .	DDI-effect
@DRUG$ study dosed with of @DRUG$ n = 7 ) ( changed n = 5 ) to a of mg five times/day	DDI-false
acetaminophen/theophylline @DRUG$/acetaminophen , , and .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
The following eight target drug/added drug combinations were studied: @DRUG$/@DRUG$.	DDI-false
Other Agents Enalapril concomitantly beta adrenergic-blocking agents nitrates , agents @DRUG$ , @DRUG$ digoxin evidence clinically significant	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Fulminant rhabdomyolysis has been seen early weeks of therapy @DRUG$ @DRUG$ may after several .	DDI-effect
Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	DDI-false
hypotensive with @DRUG$ enalaprilat be either discontinuing the increasing to initiation of treatment with or @DRUG$.	DDI-false
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water).	DDI-false
Although to examine have not been done , it was @DRUG$ or relapses for periods of to 28 days administered	DDI-false
@DRUG$ supplementation 5 ) and be carried diet with @DRUG$s with contra-indication renal failure	DDI-false
@DRUG$ : administration @DRUG$ may sodium levels possibly competing for protein-binding .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
, , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine and acid/phenobarbital	DDI-false
@DRUG$ : sodium the effect	DDI-false
@DRUG$ has reported to @DRUG$ concurrently	DDI-effect
been reported following concomitant administration of @DRUG$ potent such @DRUG$.	DDI-false
of volunteers of @DRUG$ by a of @DRUG$ , clearance by 3.8-fold p 0.05 cmax and AUC(0 8) .	DDI-mechanism
@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although have shown side effects including confusion , dyspnea with @DRUG$ may the antitumor of thus avoided . 12 and may hypotension seen .	DDI-false
@DRUG$ but not @DRUG$ decreases heart rate at high .	DDI-false
Dexamethasone and @DRUG$ similarly inhibit EGF- @DRUG$-induced of prostatic epithelium	DDI-effect
the of chemotherapy HAART the clinical course , HIV-NHL , the a patients with HIV-NHL were treated the cyclophosphamide @DRUG$ , vincristine , and prednisone CHOP ) chemotherapy regimen plus HAART group patients were with CHOP chemotherapy a CHOP-like ( i.e. , , , and @DRUG$ vincristine ) without	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
acetaminophen/@DRUG$, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Hypersensitivity reactions have reported regimens sequential high @DRUG$ and antineoplastic agents , @DRUG$ , interferon-alfa .	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
evaluate of chemotherapy on clinical course of with , lymphoma HIV-NHL authors a group who treated the cyclophosphamide , doxorubicin and @DRUG$ ( plus HAART a 80 patients CHOP chemotherapy or a CHOP-like regimen i.e. , , , teniposide , prednisone with @DRUG$ therapy .	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-mechanism
, of @DRUG$ interference phenobarbital , secobarbital glutethimide @DRUG$ and investigated in 16 patients receiving .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ , Methylxanthines : treatment derivatives , or diuretics may potentiate a hypokalemic of   @DRUG$	DDI-false
Therefore could following administration of drugs , narcotics analgesics , @DRUG$ @DRUG$ )	DDI-false
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
effect of @DRUG$ , , @DRUG$ .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
@DRUG$ other medications with anticholinergic effects may potentiated when these medications used with @DRUG$	DDI-false
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
acetaminophen/theophylline , phenobarbital/acetaminophen phenobarbital/valproic acid , @DRUG$/@DRUG$ , and	DDI-false
Exacerbation or initial presentation of of and disorders observed concurrent use of @DRUG$ and @DRUG$ , including oculo-bulbar gravis inflammatory , and Stevens-Johnson syndrome	DDI-effect
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
@DRUG$ and @DRUG$: a drug interaction.	DDI-int
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
reactions have reported in patients regimens containing sequential @DRUG$ agents , specifically , @DRUG$ , , .	DDI-effect
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy.	DDI-effect
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
neither @DRUG$ nor acetate of in they the of	DDI-effect
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Coingestion of acetaminophen @DRUG$ , phenobarbital with @DRUG$ to concentrations decreases the of	DDI-false
Lithium @DRUG$ been in receiving with drugs elimination of , including	DDI-false
, interactions following administration drugs e.g. narcotics , analgesics , @DRUG$ , @DRUG$ )	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Coingestion theophylline , phenobarbital acetaminophen and @DRUG$ with @DRUG$ to concentrations decreases binding of the .	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
@DRUG$ - prior ingestion @DRUG$ may emetic response to in the treatment poisoning	DDI-false
of @DRUG$ with 40 @DRUG$ tablets in epileptic lowered nisoldipine undetectable	DDI-mechanism
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
@DRUG$ shown to be @DRUG$ ceftazidime , on vitro time kill gram-negative bacilli .	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
of @DRUG$ with 40 SULAR tablets epileptic patients lowered @DRUG$ to undetectable	DDI-false
Acetaminophen, lidocaine, phenobarbital, quinidine, @DRUG$, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
the impact of chemotherapy plus HAART on the course of patients with HIV-related systemic HIV-NHL ) , the authors compared a group of with the cyclophosphamide , @DRUG$ , vincristine , prednisone ( regimen plus with a of 80 who were with CHOP regimen ( doxorubicin , teniposide prednisone receiving @DRUG$ .	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
phenobarbital/valproic acid , quinidine/lidocaine valproic	DDI-false
of @DRUG$ phenobarbital with @DRUG$ , and phenobarbital at toxic concentrations decreases of target drug	DDI-false
Other Enalapril and @DRUG$ used concomitantly with methyldopa nitrates @DRUG$ , hydralazine digoxin without evidence of clinically significant adverse	DDI-false
Hypersensitivity reactions been reported in regimens containing high PROLEUKIN antineoplastic agents , dacarbazine , @DRUG$ and @DRUG$.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Nephrotoxicity has following concomitant administration @DRUG$ or potent @DRUG$ such furosemide	DDI-false
The effects of ruthenium red (RR) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
To evaluate impact plus the HIV-related non-Hodgkin HIV-NHL the a group patients with the cyclophosphamide @DRUG$ , , ( ) with group CHOP chemotherapy or regimen i.e. cyclophosphamide , @DRUG$ , and prednisone with plus bleomycin ) receiving antiretroviral therapy	DDI-false
Corticosteroids , @DRUG$ treatment @DRUG$ steroids diuretics may potentiate a possible hypokalemic effect	DDI-false
Hypersensitivity reactions have reported patients receiving combination regimens containing high PROLEUKIN antineoplastic , @DRUG$ , @DRUG$ , tamoxifen interferon-alfa	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$ theophylline , with @DRUG$ , and with phenobarbital at concentrations decreases of drug .	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
, concomitant administration of psychotropic ( e.g. @DRUG$ antiemetics @DRUG$ tranquilizers	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
concomitant therapies In safety profile @DRUG$ concomitantly with , and including benzodiazepines , @DRUG$ similar to placebo with concomitant .	DDI-false
@DRUG$ ( e.g. , @DRUG$ , or amiloride ) supplements may to increases potassium	DDI-false
has been following administration @DRUG$ @DRUG$ or potent diuretics such as .	DDI-effect
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion.	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Non-steroidal Agents In some patients with function who are treated with @DRUG$ of @DRUG$ may further function .	DDI-effect
Potassium-sparing diuretics , @DRUG$ , or ) potassium supplements may lead significant potassium	DDI-false
@DRUG$ diminished @DRUG$ a change of 5.7 ( increase in drug [ FDF ] , % ) 662 micromol/L and a net change percentage % 1324 micromol/L.	DDI-mechanism
glucocorticoids been reduce PROLEUKIN-induced side effects including fever , renal insufficiency , , confusion and , concomitant agents with of @DRUG$ thus should . and @DRUG$ may potentiate the seen with PROLEUKIN	DDI-false
Other Cardiovascular @DRUG$ IV been used beta agents methyldopa , @DRUG$ , , digoxin without adverse	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
@DRUG$ other CYP3A4 e.g. , triazolo-@DRUG$ , dihydropyridine calcium channel , inhibitors , .	DDI-mechanism
Both @DRUG$-induced and dopamine release in ;	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
induce ( phenytoin @DRUG$ rifampin , @DRUG$ or St.	DDI-false
Anticoagulants including coumarin derivatives and inhibitors @DRUG$ and @DRUG$ may the when administered with ardeparin	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ phenobarbital/valproic , and	DDI-false
The zidovudine subjects with mg/day @DRUG$ ( n = changed to n ) for Days to of course 100 five of	DDI-false
Cardiovascular : and enalapril have been with beta agents , @DRUG$ nitrates @DRUG$ , prazosin and evidence of significant interactions	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	DDI-advise
@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-advise
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
@DRUG$ @DRUG$ catalyzed by aldehyde oxidase .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Gleevec will increase plasmaconcentration of other metabolized , channel blockers certain @DRUG$	DDI-false
acetaminophen/theophylline , lidocaine/quinidine phenobarbital/acetaminophen phenobarbital/@DRUG$ , ,	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
@DRUG$ had no it zidovudine tmax % increased exposure to @DRUG$ .	DDI-mechanism
The @DRUG$ are family @DRUG$.	DDI-false
It is @DRUG$ and methaqualone be safely without in prothrombin monitoring during @DRUG$ therapy	DDI-false
and acetate stimulate @DRUG$- proliferation epithelium	DDI-false
It necessary to be with clinical paraclinical of @DRUG$ and to between magnesium deficiency to magnesium which requires oral and @DRUG$ to a of the control of more or less specific of its	DDI-false
Diuretics Concomitant treatment @DRUG$ , , diuretics potentiate a effect of   @DRUG$	DDI-effect
and (ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of @DRUG$ were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.	DDI-false
the metabotropic receptor ( mGluR , @DRUG$ and @DRUG$ behavioral changes were .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
local solutions epinephrine to @DRUG$ , @DRUG$ or severe , prolonged hypotension or hypertension .	DDI-false
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
acetaminophen/theophylline lidocaine/quinidine , phenobarbital/valproic , @DRUG$/@DRUG$ , valproic	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
18-MC @DRUG$ have affinities kappa opioid and possibly receptors @DRUG$ affinities than ibogaine NMDA and sigma-2 receptors transporter	DDI-false
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Concomitant cyclophosphamide doxorubicin , @DRUG$ , and @DRUG$ chemotherapy highly antiretroviral therapy in patients human immunodeficiency virus-related , non-Hodgkin	DDI-false
The effects @DRUG$ @DRUG$ locomotion behavioral changes .	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	DDI-advise
@DRUG$/@DRUG$ lidocaine/quinidine phenobarbital/acetaminophen , phenobarbital/valproic acid theophylline/acetaminophen , valproic acid/phenobarbital .	DDI-false
@DRUG$ have been to PROLEUKIN-induced effects , hyperbilirubinemia , confusion and dyspnea administration of agents @DRUG$ may the antitumor thus should be . and other antihypertensives potentiate the seen PROLEUKIN	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Little has been studied the of exposure the liver to interaction of @DRUG$ with congeners and @DRUG$ , of beverages .	DDI-false
@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ @DRUG$ quinidine theophylline , valproic were added to pooled therapeutic	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-mechanism
@DRUG$ , 18-MC mg/kg decreases intravenous self-administration of @DRUG$ and the self-administration ethanol	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
Acetaminophen , @DRUG$ , @DRUG$ , , and acid were added to pooled at concentrations	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	DDI-false
have shown effects fever , insufficiency , hyperbilirubinemia , confusion and administration of agents reduce the effectiveness @DRUG$ thus avoided 12 Beta-blockers and antihypertensives the hypotension .	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$ : has patients @DRUG$ concomitantly with which cause elimination of sodium including ACE inhibitors .	DDI-false
Therefore interactions could occur psychotropic drugs , analgesics @DRUG$ @DRUG$ .	DDI-false
Anticoagulants coumarin derivatives indandione , and inhibitors as drugs ) and @DRUG$ may the of bleeding when administered	DDI-effect
Similarly phenobarbital , quinidine , and @DRUG$ , at therapeutic in @DRUG$ different in serum .	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	DDI-false
@DRUG$ including phenelzine , and pargyline HC1 use of @DRUG$ and non-selective inhibitors may cause hypertension .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
These results suggest that the hepatoxicity of @DRUG$ in alcoholic beverages is enhanced by interaction with its congeners and @DRUG$;	DDI-effect
These results both and acetate , and @DRUG$ may regulate proliferation epithelium a dose-dependent modification activity of @DRUG$	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Anticoagulant was during the of phenobarbital @DRUG$ and @DRUG$	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
and @DRUG$ : FORADIL with extreme caution in @DRUG$ or formoterol on the may potentiated by these .	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	DDI-false
may alter @DRUG$ Drugs increase imatinib Gleevec inhibitors of the CYP3A4 , ketoconazole , itraconazole @DRUG$ clarithromycin ) .	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
and Diuretics : with @DRUG$ @DRUG$ , may potentiate a effect .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
Drugs imatinib concentrations that @DRUG$ plasma : Caution is recommended when @DRUG$ with the CYP3A4 family e.g. itraconazole clarithromycin	DDI-false
@DRUG$, such as verapamil, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
The intake of @DRUG$ Acamprosate of either @DRUG$ or .	DDI-false
intensity , course of phenobarbital , , glutethimide @DRUG$ and investigated in patients @DRUG$ .	DDI-false
Administering @DRUG$ @DRUG$ 100 500 microM InsP(3)-induced ( Ca(2 + and responses ) in dose-dependent .	DDI-effect
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Drugs that alter plasma concentrations Drugs that imatinib plasma concentrations : is when administering @DRUG$ with inhibitors the CYP3A4 e.g. , ketoconazole itraconazole @DRUG$ ) .	DDI-advise
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), EGF (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
acetaminophen/theophylline , , , quinidine/lidocaine , @DRUG$/phenobarbital	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Other concomitant In clinical trials , the safety profile in treated with anxiolytics hypnotics and @DRUG$ ( including @DRUG$ ) , analgesics that taking placebo with medications .	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
Therefore , could occur following administration of psychotropic , narcotics , @DRUG$ , antiemetics , @DRUG$ ,	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Moreover additional studies niacin and @DRUG$ not demonstrated fluvastatin , and administration a population chronically digoxin in difference of @DRUG$ .	DDI-false
@DRUG$     @DRUG$ antagonism	DDI-false
The anesthetic solutions @DRUG$ norepinephrine to patients receiving monoamine oxidase @DRUG$ or severe prolonged or	DDI-effect
Concomitant cyclophosphamide, @DRUG$, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ ( , triamterene @DRUG$ ) potassium potassium-containing salt substitutes lead to significant serum potassium .	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
Drugs may @DRUG$ plasma concentrations Drugs that increase @DRUG$ plasma : is recommended when administering inhibitors the CYP3A4 ( , ketoconazole clarithromycin )	DDI-false
Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
@DRUG$ not affect serum @DRUG$	DDI-false
The DCG-IV L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes .	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
acetaminophen/theophylline , , quinidine/lidocaine acid/phenobarbital .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
DCG-IV @DRUG$ upon @DRUG$ behavioral in .	DDI-false
Other Agents : and enalapril have used with beta , @DRUG$ , @DRUG$ , agents hydralazine without evidence of adverse interactions .	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
The ruthenium ( @DRUG$ @DRUG$ in rat the patch-clamp whole-cell technique in combination with fura-2 microfluorometry .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although neither acetate the proliferation of epithelium in @DRUG$ the mitogenic of EGF	DDI-false
the toxicity filipin and the value @DRUG$ can be the the observations ) these @DRUG$ showed	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
evaluate the of plus HAART patients HIV-related , systemic , lymphoma ( HIV-NHL ) , the authors compared retrospectively group of 24 patients with HIV-NHL who were the CHOP plus HAART group patients who treated a CHOP-like regimen ( , @DRUG$ , @DRUG$ with vincristine plus bleomycin ) receiving antiretroviral therapy .	DDI-false
@DRUG$ phenobarbital @DRUG$ , and valproic pooled human serum therapeutic .	DDI-false
, @DRUG$/quinidine , phenobarbital/valproic acid quinidine/lidocaine , and .	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
@DRUG$ and @DRUG$ should not be administered to patients receiving coumarin drugs.	DDI-false
Myocardial injury including myocardial infarction ventricular rhabdomyolysis appear increased in patients receiving @DRUG$ and @DRUG$	DDI-effect
@DRUG$ has reported to increase @DRUG$ in human ingesting	DDI-mechanism
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
, , phenobarbital quinidine @DRUG$ , and @DRUG$ added human serum at concentrations .	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Quetiapine fumarate ('@DRUG$') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Based the studies , it is concluded @DRUG$ may coadministered zidovudine @DRUG$.	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
and @DRUG$ morphine-induced and @DRUG$-induced in the nucleus accumbens	DDI-effect
The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	DDI-effect
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-false
that , dexamethasone , @DRUG$ , carbamazepine @DRUG$	DDI-false
@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	DDI-false
Other , safety subjects treated with Acamprosate concomitantly with , @DRUG$ ( ) , or @DRUG$ was similar of subjects taking with medications .	DDI-false
to examine drug have not it noted that @DRUG$ @DRUG$ relapses periods up administered to (	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
@DRUG$ and : Concomitant @DRUG$ steroids , or may potentiate a possible hypokalemic effect	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
The administration of containing or @DRUG$ receiving monoamine oxidase , tricyclic or @DRUG$ may produce , prolonged hypotension or hypertension	DDI-effect
Other Cardiovascular Agents : @DRUG$ and IV have used beta adrenergic-blocking agents , methyldopa , , calcium-blocking agents , , @DRUG$ and without of clinically significant adverse interactions	DDI-false
Cardiovascular Agents : and enalapril IV concomitantly agents , methyldopa , nitrates calcium-blocking agents hydralazine , @DRUG$ and @DRUG$ evidence clinically significant interactions	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
concomitant of @DRUG$ and Acamprosate affect the of alcohol @DRUG$.	DDI-false
Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$ , such , @DRUG$ inhibit platelet decrease	DDI-false
@DRUG$ , phenobarbital , quinidine , @DRUG$ , added to concentrations	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
To impact of HAART on clinical patients with non-Hodgkin HIV-NHL ) authors retrospectively group of HIV-NHL were , @DRUG$ , , ( ) chemotherapy HAART 80 who treated chemotherapy or CHOP-like regimen i.e. , , doxorubicin teniposide and prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral .	DDI-false
, doxorubicin @DRUG$ plus @DRUG$ human virus-related ,	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
evaluate the impact chemotherapy on of patients with HIV-related , , non-Hodgkin lymphoma ( ) retrospectively a 24 patients with HIV-NHL treated cyclophosphamide doxorubicin , prednisone ( CHOP chemotherapy a group 80 patients were CHOP a ( i.e. cyclophosphamide , @DRUG$ teniposide , and @DRUG$ with vincristine antiretroviral .	DDI-false
Although @DRUG$ been to reduce PROLEUKIN-induced effects including fever , , confusion dyspnea , concomitant of these agents with reduce the effectiveness of @DRUG$ should be . 12 Beta-blockers other may potentiate seen .	DDI-false
These results that both dexamethasone retinyl @DRUG$ , may regulate the of epithelium a dose-dependent modification the activity @DRUG$ and EGF	DDI-effect
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
, as @DRUG$ @DRUG$ , , decrease adhesion intravascularly	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
Non-selective MAO including @DRUG$ sulfate , @DRUG$ HC1 : Concomitant of and MAO inhibitors cause hypertension .	DDI-false
However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.	DDI-false
of an effect of @DRUG$ @DRUG$ and HIV-infected patients .	DDI-false
will other CYP3A4 metabolized , @DRUG$ @DRUG$	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	DDI-false
, interaction studies @DRUG$ and propranolol have not demonstrated any fluvastatin levels and administration to a @DRUG$ resulted in the of digoxin relative data .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Moreover mechanisms of @DRUG$	DDI-false
reactions have been containing high @DRUG$ @DRUG$ , , dacarbazine	DDI-effect
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	DDI-false
of @DRUG$ of and @DRUG$ .	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
acetaminophen/theophylline @DRUG$/quinidine phenobarbital/acetaminophen phenobarbital/valproic quinidine/lidocaine , , and valproic .	DDI-false
Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ Antidepressants : should be caution treated monoamine oxidase inhibitors @DRUG$ because action formoterol on may be potentiated by these agents .	DDI-false
The safety and @DRUG$ @DRUG$ have established	DDI-false
, lidocaine @DRUG$ , @DRUG$ and valproic acid at therapeutic .	DDI-false
In clinical study , @DRUG$ or administered hypertensive	DDI-false
Other : with @DRUG$ , calcium-blocking , @DRUG$ digoxin without evidence of	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ : In patients compromised who are treated with @DRUG$ , the co-administration of enalapril may a deterioration of .	DDI-false
there no significant change in results during the of @DRUG$	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
These results suggest that both @DRUG$ and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
ibogaine 40 ) , ( 40 mg/kg ) the self-administration of @DRUG$ cocaine ethanol @DRUG$ in	DDI-false
Causing Renin Release The of enalapril enalapril augmented by @DRUG$ that cause release @DRUG$ )	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
To evaluate impact plus HAART course of with HIV-related , lymphoma ) , the a group of 24 patients with were treated with cyclophosphamide doxorubicin , vincristine and @DRUG$ ( HAART a patients were with CHOP chemotherapy a CHOP-like cyclophosphamide , , @DRUG$ vincristine plus bleomycin ) without receiving therapy	DDI-false
ibogaine ( 40 ) 18-MC ( mg/kg ) self-administration @DRUG$ and @DRUG$ and nicotine in ;	DDI-false
@DRUG$ diminished binding of @DRUG$ by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.	DDI-mechanism
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
@DRUG$ , @DRUG$ theophylline , and acid added to pooled serum at .	DDI-false
The effects of ruthenium red (@DRUG$) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
interactions could concomitant administration of drugs , @DRUG$ analgesics , @DRUG$ sedatives tranquilizers	DDI-false
Coingestion of @DRUG$ with @DRUG$, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
@DRUG$ Lithium toxicity been in receiving which elimination of	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
@DRUG$ ( ' @DRUG$ is with demonstrated efficacy the positive symptoms schizophrenia .	DDI-false
To evaluate the HAART the HIV-related systemic , ( ) authors a group of 24 patients HIV-NHL who treated the cyclophosphamide , vincristine ( chemotherapy regimen plus HAART with a of patients treated chemotherapy or CHOP-like i.e. , cyclophosphamide doxorubicin , @DRUG$ and prednisone plus @DRUG$ ) without receiving .	DDI-false
The @DRUG$ are a family of @DRUG$ and hypnotic drugs.	DDI-false
There a significant increase in to imatinib when @DRUG$ coadministered @DRUG$ inhibitor ) .	DDI-mechanism
, lidocaine/quinidine phenobarbital/acetaminophen , acid quinidine/@DRUG$ , valproic	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Concurrent drugs possessing ( e.g. aminoglycosides @DRUG$ ( cytotoxic chemotherapy cardiotoxic e.g. doxorubicin e.g. , , ) with @DRUG$ increase toxicity these organ systems .	DDI-effect
Concurrent of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ ) , , cytotoxic ) e.g. , ) or ( e.g. , @DRUG$ ) effects with increase toxicity in systems .	DDI-false
To the impact of chemotherapy on of patients with HIV-related , systemic , non-Hodgkin ( HIV-NHL ) , the authors compared of 24 patients with HIV-NHL who with the doxorubicin vincristine , and prednisone ( CHOP ) regimen a 80 treated CHOP or a CHOP-like regimen ( , cyclophosphamide , , teniposide @DRUG$ with vincristine ) receiving @DRUG$ .	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
been reported in receiving regimens sequential PROLEUKIN and antineoplastic agents , specifically dacarbazine , @DRUG$ , tamoxifen	DDI-false
days @DRUG$ treatment did significantly pharmacokinetic @DRUG$ compared with placebo	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
, phenobarbital/acetaminophen quinidine/lidocaine , and acid/phenobarbital .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
Concurrent of drugs aminoglycosides , indomethacin ) myelotoxic cytotoxic ( or hepatotoxic ( @DRUG$ @DRUG$ ) with increase toxicity in these	DDI-false
be consideration in @DRUG$ concomitantly with	DDI-advise
that induce e.g. , @DRUG$ @DRUG$ rifampin , phenobarbital	DDI-false
Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Other Cardiovascular Agents Enalapril and enalapril beta adrenergic-blocking agents , @DRUG$ @DRUG$ , and evidence of adverse	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
These suggest both @DRUG$ retinyl other glucocorticoids @DRUG$ may regulate the proliferation modification activity insulin and EGF	DDI-false
@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Clinical implications of @DRUG$ interactions with five @DRUG$.	DDI-int
Other concomitant In clinical , profile with concomitantly with @DRUG$ including benzodiazepines @DRUG$ was similar to with concomitant	DDI-false
e.g. , @DRUG$ or @DRUG$ , potassium supplements , or potassium-containing lead to significant increases in serum potassium .	DDI-false
The possibility of effects with @DRUG$ enalaprilat minimized @DRUG$ or increasing salt prior of enalapril or .	DDI-effect
Anticoagulant inhibition was observed during the administration of phenobarbital, @DRUG$ and @DRUG$;	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
use with @DRUG$s in the of	DDI-false
Although dexamethasone @DRUG$ affected the proliferation prostatic , they mitogenic of @DRUG$.	DDI-effect
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$ it 44 and the to @DRUG$ by 110 % .	DDI-false
@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	DDI-false
: trials , profile in subjects treated Acamprosate concomitantly with anxiolytics hypnotics sedatives ( including @DRUG$ , or @DRUG$ similar to of taking placebo with these concomitant medications	DDI-false
groups SH/DA ; SH/FA ) submitted to treatment with synthetic @DRUG$ methanol , higher alcohols @DRUG$ the most and fermented alcoholic ;	DDI-false
To of chemotherapy plus HAART on the clinical course of systemic , non-Hodgkin ) the authors a of 24 were treated the , , and ( ) regimen HAART with a of treated chemotherapy a ( i.e. @DRUG$ , doxorubicin , , vincristine plus bleomycin ) without receiving @DRUG$ .	DDI-false
reactions in patients receiving combination PROLEUKIN and antineoplastic specifically , @DRUG$ , , and @DRUG$.	DDI-false
@DRUG$ the proliferation of prostatic in containing they the effect of @DRUG$ insulin .	DDI-effect
Although glucocorticoids side effects including renal insufficiency , hyperbilirubinemia , confusion and , administration PROLEUKIN reduce antitumor effectiveness of @DRUG$ and avoided . @DRUG$ and other antihypertensives potentiate the hypotension with .	DDI-false
, phenobarbital/acetaminophen , phenobarbital/valproic , quinidine/lidocaine , , and acid/phenobarbital .	DDI-false
No found between @DRUG$ @DRUG$ digoxin .	DDI-false
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	DDI-advise
The administration @DRUG$ patients monoamine @DRUG$ or may produce prolonged hypotension hypertension	DDI-effect
No interactions were found @DRUG$ and warfarin or	DDI-false
Non-selective inhibitors including tranylcypromine phenelzine sulfate , and @DRUG$ HC1 Concomitant use of @DRUG$ and non-selective .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	DDI-false
The , uniformity and @DRUG$ interference @DRUG$ glutethimide chloral hydrate methaqualone were 16 receiving coumarin therapy	DDI-false
: such @DRUG$ , disopyramide @DRUG$ , , , may associated with an increased risk of	DDI-false
including derivatives , and @DRUG$ as anti-inflammatory @DRUG$ and may the concomitantly ardeparin .	DDI-false
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.	DDI-false
Lack of an effect of @DRUG$ on the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	DDI-effect
To evaluate impact HAART clinical course with , lymphoma ( HIV-NHL ) compared retrospectively a group 24 with HIV-NHL were treated the cyclophosphamide , , and prednisone ( CHOP regimen HAART a 80 patients who were with or a @DRUG$ teniposide , @DRUG$ without receiving antiretroviral .	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
, uniformity and time course of interference , @DRUG$ and were systematically investigated in receiving @DRUG$ therapy .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
MAO including @DRUG$ phenelzine sulfate pargyline : Concomitant use of @DRUG$ MAO cause	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ , @DRUG$ , triamterene , potassium-containing salt lead to significant increases in	DDI-false
In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Physiological oral @DRUG$ supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with @DRUG$s, with practically only one contra-indication: overt renal failure.	DDI-false
@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-false
Although designed to interactions have not done , it corticosteroid @DRUG$ relapses periods 28 to ( receiving @DRUG$.	DDI-false
The effects of @DRUG$ (@DRUG$) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
The pharmacokinetics of @DRUG$ major @DRUG$ unaffected co-administration .	DDI-false
@DRUG$ and similarly EGF- or proliferation epithelium	DDI-effect
, acid , , and valproic acid/phenobarbital	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
evaluate impact HAART course patients with HIV-related , non-Hodgkin lymphoma ( HIV-NHL ) authors retrospectively HIV-NHL were the cyclophosphamide doxorubicin and ( ) chemotherapy regimen plus of were treated with chemotherapy a CHOP-like regimen ( cyclophosphamide , @DRUG$ and @DRUG$ without	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
that @DRUG$ plasma may increase imatinib plasma : Caution is when Gleevec with inhibitors , , erythromycin , @DRUG$ ) .	DDI-false
Although neither nor retinyl affected prostatic epithelium in RPMI1640 @DRUG$ alone , they @DRUG$ and insulin	DDI-false
Monoamine Oxidase @DRUG$ @DRUG$ be administered with extreme in patients being oxidase inhibitors the action of the system be potentiated these agents .	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	DDI-false
Non-selective including @DRUG$ sulfate , and HC1 Concomitant L-tyrosine @DRUG$ hypertension	DDI-false
Agents @DRUG$ and enalapril have used concomitantly with adrenergic-blocking , , @DRUG$ , hydralazine , and digoxin without clinically adverse .	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
possibility hypotensive enalapril enalaprilat be @DRUG$ or increasing salt intake to of @DRUG$ enalaprilat	DDI-false
, lidocaine/quinidine , phenobarbital/valproic acid , , theophylline/acetaminophen , and	DDI-false
therefore the of @DRUG$ necessitate an in @DRUG$ levels .	DDI-false
@DRUG$ @DRUG$ inhibit and stimulate insulin-induced proliferation of	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
caution when @DRUG$ with substrates have window @DRUG$ or pimozide )	DDI-advise
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats;	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
The intensity and time @DRUG$ by secobarbital glutethimide chloral hydrate and @DRUG$ systematically patients receiving coumarin therapy .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
acetaminophen/@DRUG$ , , phenobarbital/acetaminophen acid , quinidine/lidocaine @DRUG$/acetaminophen , acid/phenobarbital	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	DDI-mechanism
acetaminophen/theophylline lidocaine/quinidine , , phenobarbital/@DRUG$ , theophylline/acetaminophen , and acid/phenobarbital	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), @DRUG$ (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
of local solutions @DRUG$ receiving monoamine oxidase @DRUG$ severe hypertension .	DDI-effect
Acetaminophen, lidocaine, @DRUG$, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Monoamine Oxidase Inhibitors Tricyclic : @DRUG$ should be with patients with monoamine or @DRUG$ of on be agents .	DDI-advise
interaction studies @DRUG$ and propranolol have not demonstrated any fluvastatin administration a patient chronically digoxin resulted no in the extent of bioavailability of @DRUG$ relative control	DDI-false
that imatinib Drugs may @DRUG$ plasma recommended administering Gleevec with inhibitors of CYP3A4 family @DRUG$ itraconazole , erythromycin ) .	DDI-false
reported patients combination high agents @DRUG$ , @DRUG$ and .	DDI-false
The , and time of by , @DRUG$ , @DRUG$ , systematically 16 patients receiving coumarin	DDI-false
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
Concomitant , doxorubicin @DRUG$ chemotherapy plus @DRUG$ patients immunodeficiency , .	DDI-false
Drugs alter imatinib may concentrations : recommended administering inhibitors of the family e.g. , , @DRUG$ @DRUG$	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
While 18-MC kappa opioid and nicotinic , @DRUG$ affinities than @DRUG$ sigma-2 receptors sodium , and the 5-HT .	DDI-false
Other : @DRUG$ disopyramide procainamide phenothiazines , antihistamines and @DRUG$ with prolongation and increased of ventricular arrhythmia	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Chloral hydrate and @DRUG$ interact with orally @DRUG$ but clinically .	DDI-int
Corticosteroids and @DRUG$ Concomitant treatment with @DRUG$ potentiate effect beta2-agonists	DDI-false
acetaminophen/theophylline , phenobarbital/valproic acid quinidine/lidocaine , @DRUG$/phenobarbital .	DDI-false
@DRUG$ ( 40 ) mg/kg decreases intravenous of and oral self-administration of @DRUG$ nicotine in	DDI-false
acetaminophen/theophylline @DRUG$/quinidine phenobarbital/acetaminophen quinidine/lidocaine , theophylline/acetaminophen , and acid/phenobarbital	DDI-false
Lithium @DRUG$ toxicity has reported in patients receiving @DRUG$ concomitantly with drugs cause of , including ACE .	DDI-false
Although have been shown to side effects , renal insufficiency hyperbilirubinemia confusion , concomitant of these @DRUG$ may reduce the antitumor @DRUG$ and thus should avoided . 12 other antihypertensives may the with	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-advise
@DRUG$/theophylline , , acid , quinidine/lidocaine valproic .	DDI-false
have PROLEUKIN-induced side effects , renal insufficiency , hyperbilirubinemia , dyspnea administration with PROLEUKIN reduce the antitumor PROLEUKIN and should be . 12 @DRUG$ other may potentiate seen	DDI-effect
@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ enhances the effect of @DRUG$.	DDI-false
The and time course of phenobarbital @DRUG$ hydrate were investigated in 16 patients @DRUG$ therapy .	DDI-false
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-effect
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
phenobarbital/acetaminophen , phenobarbital/valproic , quinidine/lidocaine , theophylline/acetaminophen , .	DDI-false
of with @DRUG$ ( microM also .	DDI-effect
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
